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Development of Ganglioside-Based Assays for the Identification of Botulinum and 
Cholera Toxins Utilizing an Evanescent Wave Biosensor 
 
Crystal M. Bedenbaugh 
 
ABSTRACT 
 
 An evanescent wave fiber-optic biosensor was used in an effort to develop an 
assay for the rapid detection of two biological toxins:  cholera toxin and botulinum toxin.  
The Analyte 2000 fiber-optic biosensor utilizes a sandwich immunoassay format.  
Gangliosides or liposomes are directly adsorbed to the surface of the fiber-optic 
waveguide through hydrophobic interactions.  The waveguide is exposed to a sample 
containing the toxin of interest, then subsequently exposed to a polyclonal detection 
antibody conjugated to the fluorophore cyanine 5.   Excitation light from a 635nm laser 
diode is propagated through the waveguide and fluorescent molecules within 
approximately 100nm of the waveguide are excited.  The emission light from the excited 
cyanine 5 molecules reverberates into the waveguide and is quantitated in pico Amperes 
and displayed on a computer. 
 The exotoxins of Vibrio cholerae and Clostridium botulinum, cholera and 
botulinum toxin, respectively, were used for potential assay development.  Assay 
development utilizing the biosensor was attempted for the detection of botulinum toxin in 
buffer.  The limit of detection remained too high to generate a positive signal for the 
detection of botulinum toxin.  Biosensor assays were developed to detect cholera toxin in 
buffer, oyster homogenate, pure culture and induction media.   
 xi  
 A cholera toxin standard curve was generated with a limit of detection of 1 ng/ml.  
The values were normalized by setting 100 ng/ml of cholera toxin to a value of 100.  
Signals were detected in oyster homogenate spiked at 5 µg/ml as well as unspiked oyster 
homogenate.  A Western blot showed that there were cross reactive proteins in the oyster 
matrix at molecular weights different from those of the cholera toxin.  Cholera toxin 
production by three strains of Vibrio cholerae with values estimated to range from 100 pg 
– 100 ng was detected with the biosensor.  Additionally, oysters were harvested from 
Tampa Bay and placed in a 10 gallon tank filled with different types of induction media.  
The tank was inoculated with Vibrio cholerae and the oysters and induction medium 
were analyzed at varying times for the presence of cholera toxin.  Vibrio cholerae cells 
were viable through 24 hours but no toxin was detectable.   
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INTRODUCTION 
Vibrio cholerae 
Background 
 Vibrio cholerae is a facultative anaerobic Gram-negative curved bacillus that is 
motile by a single flagellum.  Vibrio cholerae is autochthonous in brackish waters and 
marine environments.  Vibrio cholerae is the most clinically significant member of the 
genus.  It is the etiological agent of cholera, an acute bacterial enteric disease.   
 The organism is ingested with contaminated food or water and, due to the 
potentially destructive acidity in the stomach, requires a microbial load of 108 to 1011 for 
infection to occur (20).  The Vibrio cells will colonize the intestinal tract but they do not 
penetrate the intestinal epithelium (20).  The pathogenesis of V. cholerae is related to the 
production of an enterotoxin, the cholera toxin (CT), which inhibits fluid absorption.  The 
majority of cholera cases are mild; however, the severest form of the disease is 
characterized by rapid loss of body fluids leading to dehydration and shock (20).  Initial 
symptoms (watery stools, nausea and vomiting) begin to appear 12 to 72 hours after 
ingestion of the organism (20).   
 Historical records indicate that cholera may have first appeared in India around 
500 B.C. (24).  Since that time, seven pandemics of Vibrio cholerae O1 have occurred.  
The most recent pandemic began in Sulawesi, Indonesia in 1961 (24).  The emergence of 
a new serotype, Vibrio cholerae O139, occurred in October of 1992 in India and 
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Bangladesh.  Vibrio cholerae O139 has spread from South Asia to Near-East and 
Southeast Asia and has the potential to begin the eighth pandemic (167). 
Historical Background  
 Cholera has been a devastating disease for centuries.  Robert Koch was initially 
credited for isolating and discovering the vibrio bacillus in May of 1884 (95). Filippo 
Pacini studied the organism for 20 years but his research was ignored.  Pacini was 
posthumously credited for being the first to isolate the bacillus, V. cholerae, in 1854 (95).  
In 1965 the International Committee on Nomenclature adopted the formal name Vibrio 
cholerae Pacini 1854 in honor of Filippo Pacini and his discovery (95). 
 Cholera was originally endemic to the Indian subcontinent with the Ganges river 
serving as a reservoir (24, 25, 26).  Between 1817 and 1961 the world witnessed six 
pandemics with 1961 marking the beginning of the seventh pandemic, which is still 
ongoing (24).  The first pandemic began in Bengal in 1817, spread across India and 
extended as far as China and the Caspian Sea before ending in 1823 (24).  The second 
pandemic (1829-1851) is believed to have begun in Russia and then reached Europe and 
the Americas (24).  London, Paris, Quebec, Ontario and New York were all affected by 
the second cholera pandemic (24).  An outbreak in 1849 in New York claimed the life of 
the U.S. President James K. Polk on June 15th (45). 
 During the second pandemic in 1854, a second outbreak occurred in London.  Dr. 
John Snow lived in London at the time.  In 1849 he had proposed that cholera was 
associated with contaminated water and food, but was unable to prove his hypothesis 
(158).  With the emergence of the second outbreak, Dr. Snow demonstrated that the 
incidence of cholera was associated with contaminated food and water sources.  Dr. 
 3  
Snow conducted one of the first epidemiological studies and plotted the locations where 
cholera related deaths occurred throughout the city.  He is credited with relating the 
spread of the disease to the mixing of drinking water and sewage in Broad Street (150, 
158).   
 Russia and Europe were primarily affected by the third, fourth, fifth and sixth 
cholera pandemics with over 1 million deaths occurring in Russia (24).  Advances in 
protecting the public water supply, chlorination, water mains and the addition of sewer 
systems, led to the reduction in the number of cholera cases presented after the sixth 
pandemic.   
 The seventh pandemic began in Indonesia in 1961 and was associated with a new 
biotype – the El Tor biotype (24).  The classical biotype was responsible for the fifth and 
sixth pandemics and may have been connected with earlier pandemics.  There is no 
definitive evidence available to prove that the classical strain caused the first through 
fourth cholera pandemics but it has been associated with their occurrence.   
 In 1993, a new serogroup of cholera, Vibrio cholerae O139, was identified after a 
large outbreak of cholera-like disease in Bangladesh and India (130).  The strain of V. 
cholerae responsible for the outbreak could not agglutinate in O1 specific antiserum.  It 
was determined that the organism belonged to a new serogroup (130).  In 1994, 94 
countries reported incidence of cholera to the World Health Organization (WHO) with 
over 10,000 fatalities (64).  Twenty-one countries in Latin America reported over 1 
million cases with almost 12,000 deaths at the end of 1996 (183).  By the end of 2004, 56 
countries officially reported cases to the WHO (183, 185).  Of the 101,383 cases of 
cholera reported during that year, there were only 2,345 deaths (2.3%) (185).  Africa 
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reported a total of 95,560 cases in 2004 representing 94% of the global cases of cholera 
(185).  The number of cholera cases reported to the WHO may be inaccurate with 
individuals globally failing to identify cases and officially reporting those confirmed as 
cholera. 
 Classification.  Vibrio cholerae is a waterborne bacterium measuring 0.3 microns 
in diameter and 1.3 microns in length.  Different strains of Vibrio cholerae can be 
identified by agglutination with O-specific antiserum.  The O antigen is a cell wall 
associated component of the lipidpolysaccharide and is used to distinguish between 
strains of vibrio.  Of the more than 193 currently recognized strains of V. cholerae, V. 
cholerae O1 and V. cholerae O139 are the only serotypes pathogenic to humans (18).  
The flagellar H antigen is common to many vibrios and all O groups and, therefore, is not 
useful in distinguishing one strain of V. cholerae from another (40).  The classification 
scheme for epidemic and nonepidemic strains of Vibrio cholerae is listed in Table 1.   
 
 
TABLE 1. Classification of epidemic and non-epidemic associated Vibrio cholerae (78). 
 
Classification Serogroup Biotype Serotype CT production 
Epidemic O1 Classical and El Inaba, Ogawa Yes 
associated  Tor and Hikojima 
       
  O139 Not applicable Inaba, Ogawa Yes 
    and Hikojima 
 
Not epidemic All other Not applicable Not applicable Usually not  
associated strains    
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 The O1 serogroup can be subdivided based on antigenic differences in the B and 
C components of the O antigen (147).  The A antigen is common to all three serotypes 
and it is the B or C specific antigen that determines the serotype (147).  The antigenic 
combinations give rise to the three serotypes: Ogawa, Inaba and Hikojima (Table 2).  V. 
cholerae O1 strains are able to convert or switch between the three serotypes both in vivo 
and in vitro (147). The O139 strain has a unique O antigen and cannot be classified into 
one of the three serotypes. 
 
TABLE 2. Antigenic determinants of Vibrio cholerae O1 and O139 serotypes (147). 
 
  Serotype    Major O-antigenic determinant 
 
  Ogawa      A, B 
  Inaba      A, C 
  Hikojima     A, B, C 
 
 The O1 serogroup is divided into two biotypes, classical and El Tor, on the basis 
of phenotypic characteristics.  Biochemical tests differentiate the two biotypes (Table 3).  
Both biotypes cause cholera and their differentiation is useful for epidemiological studies.   
 
TABLE 3. Biochemical tests used to differentiation between classical and El Tor 
biotypes of Vibrio cholerae serogroup O1 (78). 
Biotype  VP test Zone around Agglutination  
    (modified polymyxin B of chicken,  
    with 1%      (50 U) goat or sheep  
       erythrocytes 
  
Classical       -        +        -        
El Tor       +        -       +        
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 Transmission. Cholera transmission occurs via the fecal-oral route through the 
ingestion of cells in contaminated food or water.  Poor, lacking or non-existant sanitation 
systems in impoverished areas allow for contamination of water systems or surface 
waters.  Use of contaminated water for drinking or in food preparation spreads the 
disease.   
 Raw vegetables (109, 122, 183), molluscan shellfish (40, 109, 122, 123), 
crustaceans (40, 109, 122) and rice (109) have been implicated in foodborne transmission 
of the disease. Filter- feeding shellfish, such as oysters, clams and mussels, will 
concentrate V. cholerae  from water into its tissues.  These types of shellfish are often 
consumed raw, which poses a higher risk of causing illness (40, 77, 98, 122).  The first 
documented case of cholera in the United States attributed to consumption of raw oysters 
occurred in 1973 in Texas (180).  Since 1973, 65 cases of cholera caused by V. cholerae 
O1 have occurred through 1991 in the United States; most cases were related to the 
consumption of contaminated shellfish (12).  Sixty-eight cases of cholera were reported 
to the CDC between 1995- 2003 and 9% were acquired through the consumption of 
seafood harvested from the Gulf Coast (15).  After the hurricanes Katrina and Rita struck 
Louisiana in October of 2005, 2 cases of cholera were reported (16).  Cholera is rarely 
seen in the United States and there is a low incidence associated with shellfish 
consumption (11, 15, 16). 
 Cholera toxin.  The pathogenesis of cholera is associated with the production of 
an exotoxin, the cholera toxin (CT) (192).  Bacterial exotoxins are produced by a variety 
of bacteria and are a type of virulence mechanism used by microorganism to assist in host 
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invasion and establishment (148).  Exotoxins are soluble, heat-labile proteins that can be 
toxic in small quantities (93).  Exotoxins may be classified into one of three categories 
based on structure and mechanism of action: (1) A-B type, (2) membrane disrupting type 
and (3) superantigen (148).  CT is a heterohexameric AB5 enterotoxin.   
 A-B toxins are composed of two subunits.  The A subunit is responsible for the 
enzymatic activity of the toxin, while the B subunit binds specifically to a host cell 
surface molecule (148).  A-B toxins are classified as simple or compound (148).  Simple 
A-B toxins, e.g., botulinum toxin, are produced as a single chain and are protealytically 
cleaved to produce one A subunit and one B subunit (148).  Compound A-B toxins, such 
as CT, are composed of multiple B subunits joined to the A subunit by a disulfide bond 
(148).  The B subunit of an A-B toxin binds to a glycolipid or a protein on the host cell 
surface (148).  Following binding of the B subunit, the A subunit is cleaved and gains 
entry into the host cell (148).   
 CT is an 84 kD protein composed of one A subunit (27 kD) and five identical B 
subunits (11.6 kD each) (103, 191, 192).  The B subunits of the CT bind a glycolipid 
cellular receptor, ganglioside GM1, on intestinal epithelial cells (33, 60, 143, 145).  The 
A subunit enters the cytoplasm of the target cell and transfers an ADP-ribose from NAD+ 
to the α subunit of the Gs protein.  The ADP-ribosylated α subunit subsequently activates 
adenylate cyclase which leads to an increase in the intracellular concentration of cAMP 
(Figure 1) (20, 74, 93).  The increase in cAMP concentration causes uncontrolled fluid 
and electrolyte flow into the intestine.   
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FIGURE 1. Mode of action of cholera toxin. A,B cholera toxin subunits; GM1 
ganglioside receptor; Gsα protein; AC adenylate cyclase; cAMP cyclic AMP (74) 
  
 The symptoms of the disease are severe diarrhea and dehydration.  Of those 
infected, approximately 75% are asymptomatic and 25% present symptoms (183).  Of 
those 25% with illness, 5% have moderate illness requiring medical attention and 2% 
face a potentially life-threatening disease (183).  Among those infected, initial symptoms 
begin to appear 12 to 72 hours after ingestion of the organism (20).  The continued 
secretion of watery feces, also called secretory diarrhea or rice-water stool, can cause an 
infected individual to lose up to 200 ml per kg of body weight per day (20).  Secretory 
diarrhea may cause death within three hours if left untreated (143).  Treatment of the 
disease consists mainly of oral rehydration with electrolyte replacement (12).  Antibiotics 
can be administered to shorten the duration of the illness. 
Epithelial cell 
GM1 
A 
B 
Gsα 
AC 
cAMP 
ATP 
A 
Na+, H2O
Vibrio choleraeCholera toxin
A 
B 
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 The LD50 in mice for cholera toxin is 250 µg/kg, which when extrapolated out 
would equal 313 mg/100 lb (53).  Consequently, a high concentration of CT is required to 
cause illness in humans.  Studies with American volunteers demonstrated that oral 
administration of up to 1011 viable virulent V. cholerae led to virtually no signs or 
symptoms of cholera.  Furthermore, cells could rarely be recovered from feces (20, 49).  
However, if stomach acid was neutralized with sodium bicarbonate, then 103 viable 
organisms could to cause the disease (49).  Another study of American volunteers 
revealed that an oral dose of 2.5 µg of purified CT caused no illness, whereas a 5 µg dose 
resulted in 1-6 L of diarrhea in 80% of volunteers and a 25 µg dose resulted in 22 L of 
diarrhea in 100% of volunteers tested (88).   
 The pathogenesis of cholera is almost exclusively dependant on cholera toxin 
production with 95% of O1 and O139 strains possessing CT producing capabilities (18, 
20, 50).  The two most important virulence factors of V. cholerae are the presence or 
production of CT and the toxin–coregulated pilus (TCP) (18, 20, 34, 58, 120, 179).  The 
ctxAB genes-the genes encoding cholera toxin- are located on the CTX element, which is 
part of the genome of a filamentous bacteriophage, CTXФ (18, 20, 34, 58, 120, 149, 
179).  The receptor for this phage is TCP, which it uses to infect V. cholerae cells (18, 20, 
34, 58, 120, 179).  Once a cell is infected, the CTXФ can become a lysogen or replicate 
extrachromosomally as a plasmid (34).  The tcp gene-the gene encoding the toxin-
coregulated pilus- is part of the V. cholerae pathogenicity island (VPI), (18, 20, 34, 58, 
120, 149, 179).  Research indicates that the VPI is of bacteriophage origin as well (18, 
20, 34, 58, 120, 149, 179).  The current hypothesis is that nontoxigenic strains of V. 
cholerae acquire the VPI through horizontal gene transfer, thus providing nonvirulent 
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strains with the ability to acquire the CTXФ and toxin producing capabilities (18, 20, 34, 
58, 120, 179).  The acquisition of the ctxAB and tcp genes makes it possible for the 
evolution of pathogenic strains from previously nonpathogenic strains of V. cholerae (18, 
20, 34, 58, 120, 179). 
 Iron.  Most bacterial organisms require iron to synthesize cytochromes and need 
to sequester iron from the environment.  In natural waters, V. cholerae must utilize a 
complex system for iron acquisition and in vivo the organism is forced to compete against 
animal hosts for iron. Humans main utilization of iron is in the proteins hemoglobin and 
lactoferrin.  Iron can be a limiting factor in microbial growth.  In order to chelate iron 
from host and environmental water systems, V. cholerae utilizes a variety of iron-
chelating siderophores to take up insoluble iron (49, 79, 100).  It is still questionable 
whether siderophores are required for increased expression of CT. 
 ToxR regulon.  The regulation of the ctx and tcp genes are controlled by the ToxR 
regulon (Figure 2) (34, 58, 131, 149, 179).  Expression of these genes is transcriptionally 
regulated by a cascade system of regulatory proteins:  ToxR, ToxS and ToxT (58, 149, 
179).  In 1987, Miller et al. (107) presented the currently accepted model that indicates 
that the ToxR regulon senses environmental signals and undergoes a conformational 
change that activates transcription of the other genes - ctxAB, tcpA and toxT -  in the 
regulon (20, 58, 131, 149).  ToxR is stabilized through interactions with the ToxS protein 
and activates transcription of the ctxAB operon and toxT gene (20, 58, 131, 149).  ToxT 
activates the transcription of tcp and ctxAB (20, 58, 131, 149).  External environmental 
conditions that influence virulence include temperature, osmolarity, medium 
composition, pH and oxygen tension (20, 58, 131, 149, 179).  It is not clearly understood 
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how the environmental signals and sensing occurs, but studies indicate that the ToxR 
regulon is influenced by environmental factors including the unknown in vivo conditions 
of the human host (20, 131).  Further analysis is needed with respect to the role of 
environmental signals and their influence on the CT virulence genes and their expression 
under the control of the ToxR regulon (20, 58, 107, 131). 
 
                                                       
 FIGURE 2. ToxR regulon.  Arrows indicate transcription activation (148). 
 
 Disease control.  Cholera is strictly a human disease and is not pathogenic to 
animals (5).  The WHO’s current recommendations for disease control focuses on 
preventing fecal contamination of water, implementing personal hygiene practices and 
managing cases with oral and intravenous rehydration therapy (184).  An effective 
sanitation system is paramount for the control of cholera transmission.  In 
underdeveloped countries where sanitation systems are not at the forefront of public 
ToxR 
ctxAB toxT 
A + B
ToxT 
tcpA 
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health concerns, cholera becomes epidemic.  Transmission is normally associated with 
contaminated water, however in areas where there is a lack of clean water the disease can 
also be spread through households via contaminated foods. 
 A parenteral cholera vaccine can be administered to those living in or traveling to 
an area where cholera is endemic (22).  However, the vaccine is not very effective, 
provides limited immunity and is short-lived – approximately 6 months (22).  An orally-
administered inactivated cholera vaccine has been field tested in Bangladesh and offers 
immunity substantially longer than the parenteral vaccine (22).  However, the CDC does 
not currently recommend the use of a vaccine and suggests those traveling to areas with 
prevalent cholera cases to seek the advice of their doctor (12).   
 In confirmed, severe cases of cholera tetracycline, doxycycline, furazolide, 
trimethoprim-sulfamethoxazole, erythromycin and chloramphenicol therapy can be 
administered to shorten the length of infection (183, 184).  Oral rehydration therapy of 
water, sugars and salts is normally recommended by the WHO (183, 184).  With prompt 
and adequate care, fatalities due to cholera can be minimized to less than 1% (183). 
Ecology and Marine Adaptations 
 Vibrio cholerae is a ubiquitous aquatic organism of brackish and marine 
environments.  It was believed that humans were the natural reservoir of V. cholerae; 
however, the ocean may actually be the reservoir for the organism (25, 26).  V. cholerae 
is found in association with phytoplankton and zooplankton (95).  A set of complex 
ecological interactions exists between cholera, phytoplankton and zooplankton that are 
required for the growth, proliferation, expression of virulence and transmission of V. 
cholerae in the ocean environment (95).   
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 Survival in the environment.  The ability of the organism to survive in food and 
water is dependent upon several variables.  Growth of V.  cholerae can be suppressed by 
the presence of other microflora (77).  Other organisms can out compete V. cholerae for 
nutrients and required growth factors therefore causing limited or no growth.  There are 
various abiotic factors that affect the survival of the organism, including temperature, 
salinity, sunlight, pH and other microflora (Table 4).  The most important physical factor 
that has a direct effect on the ecology and growth of V. cholerae is temperature (95).  
During the warmer months, higher levels of V. cholerae occur in the water column, 
which makes it is easier to isolate the organism (95).  Changes in salinity, water 
temperatures and possible seroconversion contribute to unfavorable growth conditions 
(95).  Vibrio cholerae grows optimally within a salinity range of 2-14 g per L (26).  The 
ability to tolerate fluctuations in salinity allows V. cholerae to survive and grow in 
brackish and marine waters.   
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TABLE 4. Factors affecting the survival and growth of V. cholerae in the environment 
(137).  
 
 
 Factor Effect  
 
Temperature Growth of V. cholerae above 10°C   
Salinity Growth of V. cholerae, best survival at 0.25-3 %;  
  optimum at 2% 
Sunlight (UV light) Reduces survival  
pH  Optimum 7.0-8.5 
Other microflora Survival suppressed by competitors 
 
 
  
 The role of climate change in the survival and growth of V. cholerae is still under 
investigation.  Colwell used remote sensing imagery systems to study the seasonal 
fluctuations in V. cholerae growth in marine waters (25).  Studies in Bangladesh 
indicated that cholera outbreaks occurred after sea surface temperatures and heights 
peaked (25).  Temperature models indicate an increase in global temperatures may occur 
in the next 100 years.  Without efficient public health measures an increase in global 
temperature could lead to an increase in the range and prevalence of V. cholerae (95).  
Lipp et al. proposed that CTXФ induction and propagation could increase with increased 
UV intensity (95).  It is also important to take into account natural weather patterns; 
however, it is difficult to predict the impact systems such as the El Nino Southern 
Oscillation (ENSO) have on V. cholerae growth (95). 
 When environmental conditions are unfavorable, Vibrio cholerae enters into a 
viable but nonculturable (VBNC) state with altered cell morphology (7, 27, 31, 73, 187).  
Not only do cells retain viability, but the genes responsible for pathogenicity and 
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virulence remain intact and can be expressed as well (17, 28).  VBNC cells are detectable 
by molecular methods or fluorescent microscopy when conventional laboratory methods 
fail (8, 54, 66).  During nutrient deprivation, elevated salinity and/or reduced 
temperature, the organism enters into a state of dormancy.  The shape normally 
associated with V. cholerae, a bacillus, becomes smaller with an ovoid or coccoid 
morphology (73).  The VBNC state in Gram-negative organisms has been equated to the 
spore state in Gram-positive cells (141).    
 Association with marine organisms.  Cholera has been found in association with a 
variety of aquatic organisms.  It has been suggested that there is a complex relationship 
between the growth of phytoplankton, algal plants, zooplankton and the growth of V. 
cholerae in an aquatic environment (Figure 3). 
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FIGURE 3. Abiotic and biotic factors which influence Vibrio cholerae growth and 
transmission (95). 
  
 Vibrio cholerae has been found in association with a variety of marine organisms 
including cyanobacteria (69, 95), diatoms (101), green algae (69), oysters (77, 98) and 
copepods (65, 67, 95).  The abiotic factors listed in Figure 6, temperature, pH, Fe3+, 
sunlight and salinity, directly affect the growth of plankton and aquatic plants. (95).  
Plankton growth is stimulated by temperature, nutrients and sunlight.  Proliferation of 
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algae and aquatic plants increase the survival and proliferation of cholera cells and 
provides a food source for zooplankton communities.  Research indicates that an 
association with green algae increases CT expression in V. cholerae (69).  Zooplankton 
feeds off of the plankton; therefore, an increase in plankton causes an increase in 
zooplankton. 
 Vibrio cholerae can colonize different substrates due the production of multiple 
enzymes (31).  In environmental waters, V. cholerae produces the enzyme chitinase 
which assists in its growth on chitin surfaces such as those associated with copepods (26, 
31, 46, 127).  V. cholerae will colonize copepods (Figure 4) at the oral region and the egg 
sac (67).  In the human host, mucinases are produced which enable the organism to 
penetrate the mucous barrier covering the gastrointestinal epithelium (31, 127).  V. 
cholerae will multiply until bacterial cells cover the entire egg sac.  V. cholerae feeds 
 
 
FIGURE 4.  Copepod with egg sac (144). 
 
        Egg sac 
~ 1 mm
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off of the chitin substrate of the egg sac and persists on the surface of the copepod for 
extended periods of time.  As the eggs reach maturity V. cholerae  synthesizes chitinase 
(113, 114).  The chitinase dissolves the egg sac causing the copepod eggs and V. cholerae 
to be released into the aquatic environment.  V. cholerae can also colonize the gut of 
copepods.  It has been proposed by Singleton et al. that during its association of the 
copepod CT production by V. cholerae serves an environmental role in osmoregulation of 
the copepod (157).   
 While the bacteria are attached to the copepod, they are provided with a large 
surface area, substrate, nutrients, protection from low temperatures and acidic conditions, 
and a means of transport through the environmental water system throughout the life 
cycle of the copepod (26). 
 There is a direct correlation with the number of copepods and the number of V. 
cholerae in the environment.  Large populations of copepods will aid in the proliferation 
of large numbers of V. cholerae.  With high numbers of V. cholerae in the water, filter 
feeding organisms, e.g., oysters can and will concentrate the organisms (98, 122, 164).   
 In impoverished areas where cholera is endemic and sanitation conditions are 
poor, there is a direct relationship between zooplankton populations and cholera 
incidence (95).  In areas of endemnicity, the V. cholerae and the copepods remain in the 
water due to weather and circulation patterns.  In areas of endemnicity such as 
Bangladesh, due to seasonal weather patterns of this region, seasonal increases in 
zooplankton are followed by increased numbers of cholera cases (95).  Individuals in this 
area drink contaminated water containing the copepods harboring the V. cholerae cells.  
Huq et al. demonstrated that filtering copepod contaminated water through a sari or nylon 
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cloth significantly reduced the number of cholera cases by approximately 52% (65).  In 
areas such as Japan where there are adequate sanitation facilities and cases of cholera 
appear sporadically, there is no direct correlation between increases in zooplankton and 
cholera cases (176).  
 The ecology of cholera is related directly to human disease.  One of the initial 
problems with understanding epidemics of cholera was identifying V. cholerae’s natural 
reservoir.  Researchers were initially troubled because V. cholerae could not be cultured 
from the environment between periods of cholera outbreak.  With the discovery of the 
VBNC state, scientists began to understand the cholera paradigm.  Using remote sensing 
technology, Colwell has studied the ecological relationships between V. cholerae and 
marine organisms (25).  Filter-feeding organisms in water with high concentration of 
cholera cells concentrate the organisms in their tissues.   Humans harvest and often eat 
these filter-feeding organisms raw thereby leading to illness.  CT production has been 
shown to occur in association with algae, in the gut of the copepod, or in the intestine of 
the human host.  Production of CT in each relationship ultimately benefits V. cholerae:  
allowing its survival, growth and release into the environment. 
Detection of Vibrio cholerae and Cholera Toxin 
 Vibrio cholerae. The most common laboratory procedure for recovery of V. 
cholerae from environmental samples and stool cultures involves conventional laboratory 
techniques (Figure 5) (41, 78).  Optimum growth occurs at 37°C and the organism can 
survive at ambient temperatures for approximately 5 days (11, 137).  The organism grows 
quickly at a pH of 7.0-8.5 but can survive alkaline conditions in the range of 6.0-10.0 
(137).  Many vibrios - collectively all species of Vibrio - are halophilic and require salt or 
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are stimulated by the addition of it to growth medium (132).  Cells are typically enriched 
in alkaline peptone water (APW, pH 8.5) for 6-8 hours at 37°C or plated directly onto 
thiosulfate citrate bile sucrose agar (TCBS).  TCBS, a selective medium used for the 
isolation of vibrios, offers several benefits: (1) commercial availability, (2) does not 
require autoclaving, (3) is highly selective for Vibrio spp. and (4) contains sucrose for the 
differentiation of sucrose fermenters (V. cholerae) from nonfermeters (78).  After 
isolation on TCBS, isolates are streaked onto a nonselective medium, such as tryptic soy 
agar (TSA), followed by agglutination reactions with specific antiserum and other 
biochemical tests.   
 
 
 
 
FIGURE 5.  Procedure for recovery of Vibrio cholerae from fecal specimens (78). 
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 The most probable number technique (MPN) is often used in association with 
biochemical tests to estimate population numbers in complex matrices, such as soil and 
food (122).  Cells are enriched in APW, plated on TCBS and estimated population sizes 
determined from a standard MPN table.   
Conventional laboratory techniques are inadequate for detection of vibrios in the 
VBNC state.  Molecular methods and fluorescent microscopy are used to detect VBNC 
cells (8, 66, 96).  Rapid detection methods such as PCR are commonly used for the 
detection of viable and VBNC V. cholerae cells (21).  Nucleic acid-based methods can be 
nonquantitative (42, 48, 64, 75, 80, 152) and require visualization of PCR products 
through electrophoresis (98).  Alternative PCR methods such as TaqMan PCR allow for 
near real-time detection and are quantitative (98).  The inherent weaknesses with this 
molecular method includes the inability to determine culturable cells from VBNC cells, 
PCR inhibition and the ability to only detect four genes in a single reaction (98, 122).  
DNA microarrays (182) and multiplex PCR (136) are also used to identify V. cholerae. 
 Detection of cells does not give an indication of virulence.  The Y-1 mouse 
adrenal cell assay, ELISAs, rabbit ileal loop assay and the commercially available 
immunoassay (VET-RPLA, Oxoid, Inc. Ogdensburg, NY) are used to test for 
enterotoxigenicity of V. cholerae (41, 108, 112, 126).  The Y-1 mouse adrenal assay is a 
tissue culture based method which relies on morphological changes in cell shape of the 
mouse cells for determining the presence of CT (99).  It is important to note that cholera 
toxin production is different in vivo versus in vitro (112).  A strain of V. cholerae that 
may produce toxin in the human small intestine or the mouse adrenal cells may not do so 
under a different set of conditions (112).  Unfortunately, the perfect assay does not exist 
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with an ideal set of cultural conditions that allows different strains of V. cholerae to 
maximize CT production (112).   
 ELISAs with different biological recognition elements – antibodies and 
gangliosides- are commonly used to detect CT (60, 61, 145).  The limit of detection 
(LOD) utilizing a strictly antibody based technique is 0.09 µg/ml (61).  Results using 
gangliosides as a capture molecule and antibodies as detection molecules have produced 
limits of detection in the range of 40 ng/ml to 1 µg/ml in sandwich immunoassays using 
an array biosensor with antibodies directed against rabbit and goat respectively (143).  
Dawson reported a limit of detection of 100 ng/ml when using GM1 as a capture 
molecule in a sandwich ELISA format (35).   
 The rabbit ileal loop assay is a time-consuming and cumbersome biological assay 
(36, 76).  Typically, adult rabbits are starved for a period of 24 hours, then while still 
alive a loop of bowel is ligated and injected with live V. cholerae.  At autopsy 24 hours 
later, the ileal loop is measured in length and volume for the production of CT.   
 CT. The commercially available reverse passive latex agglutination assay is 
simple to use and has a limit of detection of 1-2 ng/ml of CT (112).  The assay requires 
induction of CT production in an enrichment broth followed by subsequent detection of 
the toxin.   
 If the goal is to rapidly detect CT, then the method employed should detect CT 
and not the cells.  Very few assays directly assay for CT in a sample matrix in lieu of V. 
cholerae cells.  One assay, the bead-ELISA can directly detect CT in stool samples at a 
limit of detection between 26 pg/ml and > 100 ng/ml (129).  The beads are the solid 
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phase component of the assay and are coated with an anti-CT antibody.  The assay is 
performed in a test tube in a sandwich immunoassay format. 
 The methods described previously for the direct detection of cholera toxin are 
especially valuable because it is the toxin that is responsible for the pathogenicity of the 
organism.  However, conventional methods used to enrich for cells and then assay for CT 
can be time consuming and can give inaccurate results with respect to toxigenicity due to 
the absence of expression of necessary genes (112).  When the cells are taken from the 
environment and then enriched and grown in the laboratory under ideal conditions, 
specific genes can be turned on, off, rearranged or lost in the process (126).  A rapid, 
sensitive and specific assay is necessary for the direct detection of CT. 
Clostridium botulinum 
Background 
 Clostridium botulinum spores are ubiquitous in soils and aquatic sediments 
worldwide (159).  The bacterium is a Gram-positive obligate-anaerobic sporulating rod 
that measures 0.5-2.0 µm in width by 1.6-22.0 µm in length.  Clostridium botulinum is 
the etiological agent of food-borne botulism, an intoxication caused by the ingestion of a 
potent exotoxin, botulinum toxin (148).  Botulinum toxin is a neurotoxin and is classified 
into seven different serotypes, A-G, with types A, B, E and F causing the most serious 
disease in humans: botulism (68, 84, 159, 163, 181, 190).  Botulism is a paralytic illness 
caused by the action of the neurotoxin at the vertebrate neuromuscular junction (23).  The 
neurotoxin blocks the release of the neurotransmitter, acetylcholine, at the peripheral 
cholinergic nerve endings leading to respiratory and musculoskeletal paralysis (23, 102).   
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There are three main kinds of botulism: (1) foodborne botulism caused by the 
ingestion of preformed toxin; (2) wound botulism caused by toxin produced from a 
wound infected with C. botulinum; and (3) infant botulism caused by consuming the 
spores of the bacterium which sporulate in the intestines and release toxin (68, 84, 102, 
124, 140, 159, 163). 
 Virulence factors.  The neurotoxin produced by C. botulinum is the most potent 
biological toxin known with a minimum lethal dose in monkeys of 0.5 ng when 
administered orally (53), 0.00625 ng in mice when administered intraperitoneal (59) and 
an estimated LD50 in humans of 1 ng/kg for type A toxin (53, 63).   
All seven neurotoxins are similar in their mode of action and are simple A-B 
toxins.  The toxin is produced as a single protein chain and then protealytically cleaved to 
produce one A subunit and one B subunit (148).  The complete toxin has a molecular 
weight of approximately 150 kD and is composed of one heavy chain (B subunit) and one 
light chain (A subunit) linked by a disulfide bond (84).  The active toxin heavy chain  
(approximately 100 kD) is responsible for the recognition of specific neuron receptors 
and mediates the internalization of the light chain into the cytosol (68, 124, 140, 163).  
The light chain (approximately 50 kD) is responsible for the intracellular activity; 
blocking the release of acetylcholine at the neuromuscular junction leading to flaccid 
paralysis (68, 124, 140).   
The action of the neurotoxin is caused by a series of events.  The heavy chain 
binds a co-receptor complex, the glycoplipid cellular receptor, (GT1b, GD1b, GQ1b or 
GD1a), and the protein synaptotagmin II (19, 84, 116, 117, 156, 190).  After binding, the 
receptor-ligand complex is internalized via endocytosis, the light chain is translocated 
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into the cytosol and acts on nerve endings by inhibiting the release of the 
neurotransmitter, acetylcholine (68, 84).  The continued inhibition of acetylcholine 
release causes flaccid paralysis that may eventually lead to respiratory failure if the 
paralysis extends to the respiratory muscles (59). 
 Symptoms begin 18-24 hours after ingestion of the toxin and include double 
vision, blurred vision, slurred speech, difficulty swallowing and muscle weakness (53).  
The intoxication is characterized by cranial nerve palsies followed by symmetrical 
descending flaccid paralysis of motor and autonomic nerves (157, 163).  Patients remain 
fully alert until death (53, 159).  If detected early enough after the ingestion of the toxin, 
(usually within the first 24 hours of symptoms appearing), botulism can be treated with 
trivalent antitoxin (types A, B and E) which halts the progression of paralysis and 
shortens the length of the illness (148, 159).  The antitoxin acts by neutralizing any free 
toxin in circulation; thereby, inhibiting the toxin from binding to nerve endings (148, 
159).  In the United States, more than 80% of patients are treated with antitoxin (13).  If 
the presence of the toxin is detected after the neurotoxin has begun to effect nerve 
endings and cause damage, supporative care is given to the patient (13, 53, 148, 159).  
 Types of botulism.  Botulism is commonly acquired through ingestion of toxin in 
food that has been improperly prepared prior to its consumption (53, 102, 159).  
Foodborne botulism is rare in the United States and is usually associated with home-
canned vegetables, fruits and meat products (13, 148, 159).  Spores survive in foods that 
are incorrectly processed and are only inactivated by heating to 121°C under pressure of 
15-20 lb/in2 for at least 20 minutes (159). Toxin production only occurs in an anaerobic 
environment with a low salt concentration and a minimum pH of 4.6 (13, 159).  Between 
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1950 and 1996, the CDC reported 444 cases of foodborne botulism with a case-fatality 
ratio of 15.5% (13).  A total of 263 cases were reported to the CDC between the years 
1990-2000 (159).  Of those cases, there was a case-fatality ratio of 4% (159).  In 2003, a 
total of 8 cases of foodborne botulism were reported to the CDC with a case-fatality ratio 
of 25% (15). 
 Infant botulism is the most common form of botulism in the United States (14, 85, 
163).  Infant botulism was first recognized in the United States in 1976 when the toxin 
and/or cells were detected in the feces of infants (163).  This type of botulism is an 
infection with spores obtained from contaminated honey (163).  The spores temporarily 
colonize and germinate in the intestine of the child and produce toxin.  It is recommended 
that infants who are still nursing should not be given honey (163).  Symptoms include 
constipation, trouble sucking, swallowing, or crying and progressive muscle weakness 
(14).  The CDC reports the annual incidence of infant botulism is 2 per 100,000 live 
births (13). 
 Wound botulism results from the colonization of a wound with C. botulinum 
(133).  When the skin is compromised and contact with contaminated soil or gravel 
occurs, the tissue may become infected with C. botulinum.  This form of botulism is very 
rare and disease results in the production of neurotoxin, which travels through the 
bloodstream and to the nerves (133).  Symptoms are similar to those associated with 
foodborne botulism without the gastrointestinal involvement:  blurred vision, sore throat, 
trouble swallowing and the eventual culmination in paralysis and death.  Wound botulism 
was first recognized in 1943 and through 1990, only 47 cases were reported to the CDC 
(59, 133).  Since 1990, the majority of wound botulism cases have been associated with 
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IV drug use (9, 110, 121, 133).  Between 1990-2002, 210 of 217 cases reported to the 
CDC were associated with IV drug use (133). 
 Due to the potency of the neurotoxin, botulism is a major threat as a bioweapon 
(3).  The toxin can be aerosolized and cause the same disease as foodborne botulism 
through inhalation.  One gram of aerosolized toxin has the potential to kill 1.5 million 
people (3, 121).  The 1972 Biological and Toxin Weapons Convention prohibited the 
offensive development of bioweapons (94); however, Iraq continued to develop their 
weapons program (3).  Iraq disclosed to the UN Security Council after the Gulf War of 
1991 that over 19,000 L of concentrated botulinum toxin had been produced (3, 193).  Of 
the 19,000 L, 10,000 L had been loaded into military weapons for use (3).  Due to the 
serious threat botulinum causes as a bioweapon, the CDC continues to monitor any 
reported cases. 
Detection of Clostridium botulinum and Botulinum Toxin 
 Botulism is most effectively treated soon after the appearance of symptoms. 
Rapid diagnosis is important due to the damage exerted on nerve endings.  Currently, the 
mouse bioassay is the gold standard for the detection of botulinum toxin or for 
differentiation of serotypes (1, 47, 53, 59, 118, 181).  Mice are injected with an 
intraperitoneal dose of botulinum toxin and observed for a period of four days (4, 47, 
181).  Animals are observed for symptoms of botulism; those injected with higher doses 
show symptoms within 8 hours while those injected with lower doses can take a few days 
to develop symptoms (4).  The limit of detection for the most active serotype is 10-20 
pg/ml (4, 181).  The mouse bioassay has several disadvantages: (1) it takes several days 
for results; (2) many animals are required for the assay; (3) special facilities are required; 
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(4) there are inherent hazards associated with injecting the mice; (5) it is expensive; and 
(6) additional testing is required to differentiate neurotoxin serotypes (4, 47, 181). 
 ELISAs have been developed in lieu of the mouse bioassay for the detection of 
the botulinum toxin (4, 47, 59, 181).  The ELISA allows for the screening of a larger 
sample size with more rapid results without the need for animals.  Ferreira et al. reported 
a limit of detection of 10 minimal lethal dose (MLD) per ml (47).  The current MLD 
currently is 0.02 ng for type A toxin (47).  Wictome et al. reported a limit of detection of 
0.5 MLD per ml when utilizing a colorimetric immunoassay for type B toxin (181).  
Signal amplification was used in conjunction with an ELISA by Sharma et al. in several 
different types of food matrices including liquids, solids and semi-solids and generated 
extremely sensitive limits of detection for toxin types A, B, E, and F (153).  The limits of 
detection for the four different serogroups were as follows:  type A toxin was 60 pg/ml, 
type B was 176 pg/ml, type E was 163 pg/ml and type F was 117 pg/ml (153).   
The use of affinity molecules other than antibodies in association with botulinum 
toxin is also being employed in conjunction with an ELISA.  Liposomes containing the 
natural cellular receptor for botulinum toxin, (GT1b, GD1b or GQ1b), and fluorophore-
labeled lipids have been used as detection molecules in a sandwich fluoroimmunoassay 
(156).  Concentrations as low as 1nM of botulinum toxin could be detected with 
fluorescently labeled liposomes (156).  Another receptor immunoassay was developed 
with GT1b inserted into a liposome (1).  In this assay, botulinum toxin was detected as a 
colored band on a nitrocellulose membrane either visually or with a densitometer (1).  
The limit of detection for this assay with type A toxin was 15 pg/ml (1).  Current ELISA 
assays are not sensitive enough to replace the mouse bioassay and make take up to 5 days 
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for the cultures to produce toxin; therefore, they do not produce results in a near-real time 
fashion (118).  There is a need for a rapid and sensitive test and assays utilizing 
molecular techniques and biosensors are being developed as an alternative to the ELISA 
and mouse bioassay. 
PCR can be used to identify toxin genes in 24 h botulinal cultures as type A, B, E 
or F neurotoxin producers (32, 161).  PCR uses nucleic acid probes which, under 
controlled conditions, hybridize with the complementary nucleic acid sequences of 
interest. Clostridium botulinum isolates are enriched anaerobically for 24 hours to obtain 
vegetative cells.  A simultaneous PCR reaction for all 4 toxin serotypes can then be 
performed.  The PCR may be used in conjunction with the mouse bioassay as a 
confirmatory test (32, 161).  This type of PCR assay does not produce real-time results 
but merely shortens the time interval with which a diagnosis could be provided.  Real-
time PCR assays have been developed for the detection of type A, B and E toxins from 
purified DNA samples and crude DNA extracted from broths (2).  Using real-time PCR, 
seven out of eight botulinum cases were identified which provided a faster preliminary 
diagnosis than conventional bioassays (2).   
A fiber optic-based biosensor assay utilizing a sandwich immunoassay produced a 
limit of detection of 5 ng/ml for botulinum toxin type A (118).  Immobilized antibodies 
were used as a capture molecule and fluorescently labeled antibodies were used as a 
detector.  The toxin detection occurred in one minute with previously prepared fibers.  
The assay provided sensitive results with no cross-reactivity to the similar toxin, tetanus 
toxin. 
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Immunoassays 
Background  
 Immunoassays have been in use since the 1960s when Rosalyn Yalow and 
Solomon Berson used a radioimmunoassay to detect and quantify insulin in plasma 
samples (188).  These assays combine the principles of biochemistry and immunology, 
enabling scientists to detect very low concentrations of a specific antigen.  The principle 
of the test involves using antibodies as reagents.  In an immunoassay, the antibody at a 
specific concentration - either a primary or secondary - is attached to a label: an enzyme 
(enzyme immunoassay; EIA), a radioisotope (radioimmunoassay; RIA) a fluorescent dye 
(fluorescent immunoassay; FIA) or a luminescent label (luminescence immunoassay; 
LIA).  The conjugation of the antibody to one of these labels provides the means for 
determining the concentration of an unknown antigen.  Depending on the type of label 
conjugated to the antibody, a color change, emission of light, the amount of radioactivity 
or some other signal is produced and measured after the immunological binding reaction. 
Special visualization systems including spectrophotometer, fluorometer and luminometer 
are required to quantitate the amount of label or end product present. 
 Enzyme immunoassays (EIA) are the most widely used type of immunoassay.  A 
large number of samples and complex antigens such as bacteria can be assayed using EIA 
(139).   Sensitivity, the ability to detect low levels of antigen, and specificity, the ability 
to differentiate between antigens, are two ways assays can be described.  Sensitivity and 
specificity are both dependent on the antibody antigen interaction.  EIAs are easy to 
perform and involve the basic principle of antibody-antigen interaction:  typical 
interactions are highly sensitive and very specific.  Thus, immunoassays are practical 
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when an unknown concentration of an antigen needs to be quantified.  In a sandwich 
assay, an antigen is sandwiched between two antibodies: a capture antibody immobilized 
on a solid surface and a detection antibody with a label.  In a direct assay, cells or antigen 
are adsorbed to wells of a microtitre plate.  The method of detection with different assay 
formats can be divided into two categories: direct and indirect. 
Detection Format 
 The direct sandwich immunoassay (Figure 6a) uses two layers of antibodies to 
detect antigen.  Antigen of interest must have at least two antigenic sites: one to bind 
capture antibody and one to bind labeled detection antibody.  Antibodies are attached to a 
solid surface to capture antigen.  Labeled primary antibody binds directly to the antigen 
and is detected by the label.  If the label is an enzyme, such as peroxidase or alkaline 
phosphatase, substrate is added and the unknown concentration of the antigen is 
determined.  If the label is a fluorophore, such as Cyanine 5 or rhodamine, under the 
appropriate wavelength of light, it fluoresces and antigen concentration is quantified. 
 
   
 
 
 
 
FIGURE 6a.  Direct detection with sandwich immunoassay. 
label
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FIGURE 6b. Indirect immunoassay detection with direct adsorption. 
 
 Passive adsorption allows ELISA reagents, antibody or antigen, to attach 
passively to the solid phase of a surface during an incubation step.  In an indirect assay, 
antigen binds to capture antibody followed by the addition of primary antibodies (Figure 
6b).  A binding event occurs between the primary antibodies that have an affinity for the 
antigen of interest.  The binding of the primary antibody is followed by incubation with 
labeled secondary antibodies directed against the species in which the primary antibody 
was made.  Upon binding of the labeled secondary antibody, antigen concentration is 
determined. 
 Given these two detection formats, it is imperative to have high quality antibodies 
with good specificity and an advanced detection system in order to develop a quality 
immunoassay.   
Antibodies   
 Immunoglobulins, or antibodies, are a group of secreted glycoproteins found in 
the serum of all animals.  The production of antibodies occurs at the culmination of a 
series of events between B lymphocytes and effector cells of the immune system.  When 
a mature B cell encounters a specific antigen, it will undergo activation, proliferation and 
label
Secondary antibody
Primary antibody
antigen
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differentiation leading to the eventual production of antibodies (139).  Antibodies 
perform two key functions; they bind antigens and some mediate effector functions 
throughout the body: fixation of complement and binding to various cell types (139).  
Antibodies are extremely specific thus making them an ideal molecule for the use in 
assays to detect a variety of substances. 
 There are five classes of antibodies, IgG, IgA, IgM, IgD and IgE, determined by 
amino acid sequence differences in the constant region of the heavy chain.  The 
antibodies of the class IgG are the most prevalent antibody in serum and the most 
commonly used in immunoassays.  IgG antibodies have a molecular weight of 
approximately 150 kD and are composed of two light and two heavy chains.  B 
lymphocytes are capable of making over 18 billion antibodies through a variety of 
mechanisms: site-specific recombinations, mutations, random gene splicing, splicing 
inaccuracies and class switch recombination (139).   
 Antibodies need to be specific with a high affinity for the target antigen for use in 
immunoassays (97, 134, 166).  Affinity is the strength of the bond between the antigen 
and antibody.  In order to detect antigen in low concentrations, the affinity of the 
antibody must be high.  The antibodies must be stable and have low cross reactivity with 
other molecules.  If an antibody has a high degree of cross-reactivity with other 
molecules aside from the antigen of interest, then quantitation of the antigen could be 
inaccurate.  When selecting an antibody for a particular application, it is important to 
choose one that provides the greatest amount of sensitivity with the least amount of cross-
reactivity.   
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 The antigenic determinant, or epitope, is a single antigenic site to which the 
antibody binds.  The size of an epitope is normally 6-8 amino acid residues.  A single 
antigen can have multiple epitopes.  In an immune response, if the antigen is large (e.g., a 
bacterium), animals will produce a large number of antibodies from different B cells.  
Each B cell will produce its own type of antibody.  These antibody producing cells 
manufacture antibodies that recognize different epitopes on the same foreign molecule.  
This heterogeneous mixture of antibodies is found in the serum of animals.  The natural 
collection of antibodies produced from different B cell lines is called polyclonal 
antibodies.  Polyclonal antibodies used for research purposes are normally made from 
goat, rabbit or sheep (57).  Polyclonal antibodies are the most commonly used antibodies 
for immunoassays (57).  These antibodies remain stable for approximately one year at 
4°C when in suitable buffers and held at high protein concentrations of 1 mg/ml (57).  
 Monoclonal antibodies are produced by only one type of B cell and can recognize 
only a single type of epitope on a complex antigen.  In 1975, Köhler and Milstein 
developed the first hybridomas by fusing together mouse myeloma cells and lymphocytes 
from the spleens of mice that had been immunized with a specific antigen (81).  The 
hybridomas combine the immortality of the myeloma cell with the antibody producing 
ability of the lymphocyte.   
 Monoclonal antibodies are directed against a single epitope and therefore can 
function as a capture or detection molecule within the constraints of the same assay.  
Monoclonal antibodies generated from the same clone would compete against itself for 
the same epitope if it were used as both the capture and detection molecule in the same 
immunoassay.   
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Labels   
 In order to detect and quantify an antigen, antibodies must be conjugated to a 
label.  The presence of labeled directly correlates with the concentration of antigen.  The 
original label used for immunoassays was the radioisotope (125).  Since the development 
of the immunoassay, different enzyme labels with a matching substrate or fluorophores 
have been used to produce measurable end products.  Enzymes used for colorimetric 
assays include horseradish peroxidase and alkaline phosphatase.  Chromogenic, 
flurogenic and chemiluminescent substrates can be used with either enzyme.  
Fluorophores, such as rhodamine, can be used as an antibody label.  Also, enzymes for 
the detection of chemiluminescence (peroxidase-catalyzed luminol assays) are used in 
immunoassays.  In order to utilize the immunoassay without the constraints of 
radioactivity, enzymatic, fluorescent and chemiluminescent labels are replacing 
raidioisotopes (125).  
 Most enzymatic detection systems offer an equal or better detection capability 
than the radioactive systems without the dangers associated with radioactivity.  When 
using an enzymatic tag, samples can be read with a spectrophotometer, luminometer or 
fluorometer.  In order to get faster and better results, fluorescent and chemiluminescent 
systems are employed (125). 
 Fluorescent labels provide a powerful label in immunoassays.  Typically, the 
results produced from a fluorescent label are more sensitive and can be obtained quicker 
than an enzymatic or colorimetric assay; however, their potential can be limited if dyes 
are not stable and there is sample interference (57).  Also, a complex and expensive 
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instrument for the detection of fluorescence, a fluorometer, is required if a fluorescent 
label is chosen.   
 Chemiluminescent tags are the most sensitive and require the fewest amount of 
reagents of the four labels mentioned (89, 106, 189).  Unlike colorimetric or fluorescent 
assays, samples assayed with chemiluminescent tags contribute little to no inherent 
background interference (106).   
 Regardless of the label and detection system employed, all immunoassays are 
based on the same antigen-antibody interactions.  Therefore, the specific interaction of 
antigen and antibody is very important for low limits of detection-the smallest 
concentration measurable with a particular assay-making immunoassays applicable to a 
wide variety of compounds of interest.  Colorimetric, fluorescent and chemiluminescent 
assays are safer and more sensitive than radioimmunoassays and have therefore become 
more popular in use and application. 
Biosensors 
Background  
 There is an increased demand for detection systems capable of producing 
sensitive and specific results within a relatively short period of time.  The need for this 
type of detection system spans different types of industries: environmental, agricultural, 
pharmaceutical, food and public health (87).  Biosensors are analytical detection devices 
which utilize biological molecules to detect other biomolecules or chemical substances.  
All biosensors exploit the ability of biomolecules to specifically recognize a target 
analyte, a substance an assay aims to detect.  Biosensors combine this specific interaction 
or affinity between a biomolecule and its target with signal generation near or directly at 
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the surface of a transducer (Figure 7) (30).  The transducer takes one type of energy and 
converts it to another.  After the molecular recognition between biomolecule and analyte 
occurs, a signal is produced that can be coupled and converted by the transducer into a 
signal that can be measured (30).  The signal produced by the transducer, (e.g. 
electrochemical, optical or thermal), corresponds to the concentration of the target (30).  
Biosensors have existed since the 1970s but the interest in developing sensors for near 
real-time/real-time detection has lead to advances in their development (186).  Different 
types of affinity systems can be used in conjunction with a biosensor, including the 
following: enzyme-substrate, antibody-antigen, receptor-ligand, lectin-sugar or nucleic 
acid for complementary sequence hybridization (30).   
 
 
FIGURE 7. General principles of a biosensor (138). 
  
 Immunoassays are frequently used in conjunction with biosensors.  As described 
previously, antibodies are most commonly used; however, other biomolecules are also 
used to recognize and bind target.  These biomolecules can be immobilized to the solid 
surface platform through passive adsorbption, linked through a biotin-streptavidin bridge 
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or covalently attached to serve as capture molecules (154).  A detection molecule, which 
also recognizes the target, is tagged with an appropriate label and is used to generate a 
measurable signal (92).  Biosensors are not without their disadvantages: some are 
expensive, produce inconsistent results or are bulky and not practical for in the field use.  
However, biosensors offer several advantages over conventional laboratory techniques.  
Biosensor assays are generally easier to perform and do not require trained personnel 
(92).  For example, home pregnancy tests and glucose monitoring systems are bioassays.  
A home pregnancy test utilizes monoclonal antibodies directed against HCG to produce a 
colorimetric change.  The over the counter home pregnancy test is a notable example of 
an effective biosensor: it is inexpensive, disposable, simple and accurate.  Due to the 
specific recognition required between biomolecule and analyte, biosensors generate high 
degrees of sensitivity and specificity.  Near real-time/real-time detection in complex 
matrices is also an advantage frequently derived from the use of a biosensor (37, 38, 39, 
92).  Finally, fully automated biosensor assays that can operate unattended have the 
potential to be integrated into on-line monitoring systems in water treatment plants or 
food processing facilities. 
Types of Optical Biosensors   
 Optical biosensors utilize optical grade glass, plastic or silicon fiber to transmit 
light from one position to another.  Light is propagated through the interior core of the 
fiber and reacts with reagents that are placed near the surface of the fiber.  The light 
emission is converted into a quantifiable signal and the intensity correlates with the 
concentration of the unknown target.  The transducer (a monochromator, lenses and 
photomultiplier tube) receives a signal and collectively converts it into an electrical signal 
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that can be recorded (87). Types of optical biosensors include surface plasmon resonance, 
fiber optic and evanescent wave.   
Evanescent wave Fiber-Optic Biosensor  
  One type of optical biosensor is based on evanescent wave technology.  An 
evanescent wave fiber-optic biosensor uses the principle of total internal light reflection 
(Figure 8).  Electromagnetic waves of light are propagated within the waveguide and a 
portion of it travels outside the core and is referred to as an evanescent wave.  When 
biomolecules labeled with fluorophores fall within the range of the evanescent wave  
(approximately 100-1000 nm), the fluorophores become excited by the light source and 
the fluorescent signal is coupled back through the fiber.  A photodiode allows for 
quantitation of the light emitted from the fluourophores within the range of the 
evanescent wave.  
 One type of fiber-optic evanescent wave biosensor detection system is the 
Analyte 2000 (Research International, Monroe, WA), which uses an optical fiber as the 
waveguide (37, 38, 39, 43, 85, 86, 91, 92, 155, 170, 171).  The Analyte 2000 utilizes a 
sandwich immunoassay based on the specificity of antigen-antibody or receptor-ligand 
binding.  An immobilized, capture biomolecule is attached to a fiber-optic waveguide 
through a streptavidin-biotin bridge or passively adsorbed.  This waveguide is exposed to 
a substance containing the suspect antigen and then subsequently exposed to a detection 
biomolecule conjugated to a fluorophore.  Excitation light from a 635 nm laser diode is 
propagated through the waveguide and fluorescent molecules within approximately 100 
nm of the fiber are excited (92, 178).  The emission light from the excited fluorophore 
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reverberates into the waveguide and is quantitated in picoamps and displayed on a 
computer. 
 
 
 
 
 
 
     
 
FIGURE 8. Total internal reflection in optical fiber (154).  The propagation of 
electromagnetic waves in optical fiber by total internal reflection.  A portion of the light 
travels just outside the core, approximately 100 nm, and is referred to as the evanescent 
wave or field. 
 
Affinity-Based Elements 
 There are a wide variety of biomolecules that can function as capture and/or 
detection molecules in conjunction with biosensors including antibodies, receptors or 
nucleic acids (70).  When selecting an affinity-based recognition element for use with the 
biosensor, it is important to consider the application of the assay.  The biomolecule 
should be selected based on its ability to minimize non-specific binding and increase 
specificity and sensitivity (70, 162).  Antibodies, either monoclonal or polyclonal, are the 
most commonly used recognition molecule in conjunction with biosensor assays (70, 97).  
Theoretically, polyclonal antibodies would not compete for the same epitope and could 
be used as both a capture and a detection molecule.  Monoclonal antibodies from the 
same clone would theoretically compete for the same epitope if used as a capture and 
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detection molecule.   Therefore, it would seem advantageous to use polyclonal antibodies 
as both detection and capture molecule or a combination of polyclonal and monoclonal 
antibodies.   
 The receptor/ligand relationship offers an alternative to antibodies in developing 
biosensor assays (162).  Receptors are cell surface molecules, either cytoplasmic proteins 
(steroid receptors) or transmembrane receptors (gangliosides), which exhibit specificity 
for a particular effector molecule (105, 135, 143, 174).  As in antibody interactions, 
receptors may bind their respective ligands with low or high affinities.  High affinity 
interactions are desirable in biosensor assays.  Ganglioside receptors are 
glycosphingolipids widely distributed in all tissues but heavily concentrated in the central 
nervous system of animals (105, 174).  Gangliosides are natural cellular receptors for 
toxins and like antibodies, rely on specific interactions with ligands.  Common 
gangliosides include GD1a, GD1b, GD2, GD3, GM1, GM2, GM3 and GT1b (82).  Viral 
and bacterial pathogens exploit the natural relationship between ganglioside/ligand 
interactions to gain entry into host cells (105, 143, 164, 174).  Binding of these pathogens 
to ganglioside receptors can be utilized for detection.  Gangliosides can be used as 
capture molecules when immobilized on solid surface assay platforms or labeled with a 
tag and used as a detection element (105, 143, 162, 165, 174).   
 Another non-antibody based biological interaction used with biosensor assay 
development is the nucleic acid probe that can specifically hybridize with its 
complementary sequence.  A nucleic acid probe is a segment of DNA designed 
specifically to a nucleic acid target.  Unlike antibodies or receptors, nucleic acid 
recognition elements can only bind and interact with molecules containing RNA or DNA.  
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These probes lack the ability to detect proteins, chemicals or other biological molecules.  
Recognition of the target nucleic acid is dependent on the formation of stable hydrogen 
bonds between the complementary nucleic acid probe and its target (70).  Nucleic acid 
probes can be used for either capture or detection. 
 Antibodies, receptors and nucleic acid probes, can be used in a variety of assay 
formats.  One type of element may be used as both the capture and detection molecule or 
a combination of recognition molecules can be used in unison with one another.  Using 
more than one type of element per assay could limit the amount of competition that 
occurs for binding sites as long as the two elements do not bind to the same epitope.  If, 
in the same assay, a ganglioside and an antibody are used together as capture and 
detection molecule, respectively, than theoretically they are not competing against one 
another for the same recognition site.  This type of assay could then potentially increase 
the specificity of the assay due to the double recognition of the target analyte. 
Summary 
 Millions have suffered and thousands have died from the virulent toxin released 
from the cells of V. cholerae.  Cholera is transmitted through the fecal-oral route and 
there is a higher incidence of infection and endemnicity in areas with poor sanitation.  
The cells of V. cholerae are best adapted to marine and brackish waters and exist in either 
a commensal or symbiotic role with marine organisms.  Cholera occurs most often in 
populations with low socioeconomic status:  sanitation facilities are poor or nonexistent, 
personal hygiene practices are wanting and the people lack the education to understand 
the disease.  Eradication of the disease may be too big of a task for national or 
international control programs.  However, measures can be taken for quick detection 
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followed by containment of the disease.  The most critical element of cholera control 
during an epidemic is the early identification of the illness, proper notification of health 
officials, adequate healthcare facilities and the disposal of raw sewage (7). 
The neurotoxin produced by C. botulinum is one of the most lethal biological 
toxins known.  Botulism is rarely seen manifested in society; however, it is possible to 
suffer lethal food poisoning with improperly processed foods.  Recent world events have 
focused the world’s attention and raised awareness to the potential use of this toxin as a 
biological agent against our military and civilian populations.  Botulinum toxin is 
relatively easy to obtain or produce and the intentional contamination of food or water 
supplies remains a viable threat. 
The purpose of this research was to develop a sensitive and specific assay 
utilizing gangliosides in conjunction with the fiber-optic evanescent wave biosensor to 
detect biological toxins.  The biosensor immunoassay is a detection system that has the 
capability to produce rapid, sensitive and specific results in near real-time.  Gangliosides, 
recognition elements other than antibodies, were used as capture or detection molecules.  
Assay development was performed using CT as the model protein. Once a rapid, 
sensitive and specific assay was developed to detect CT in buffer using the biosensor, the 
method was applied to the detection of the toxin in oysters.  Shellfish, specifically oysters 
when ingested raw or undercooked, have been implicated in the transmission of cholera 
(40, 109, 122, 123).   
The pathogenicity of cholera is directly related to the production of CT.  A rapid, 
sensitive and specific assay is necessary for the detection of CT in contaminated water 
and food.  The majority of assays used to assess contamination of food and water with V. 
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cholerae rely on conventional laboratory techniques: enrichment, isolation, serological 
and/or biochemical tests.  The presence of CT genes can be detected through PCR; 
however, enrichment is often needed and the assay fails to determine if the protein is 
being expressed. Vibrio cholerae cells recovered from contaminated food or water can be 
induced in vitro to produce CT.  This type of assay can assess the virulence of the strain 
but is time consuming.  Enrichment followed by inoculation into induction media is 
needed to induce the organism to produce the CT.  For these reasons, utilizing the 
evanescent wave, fiber-optic biosensor is an innovative means of detecting CT directly 
from matrices. 
After the CT biosensor immunoassay was developed in combination with 
gangliosides, the protocol was used in assay development for the detection of botulinum 
toxin.  The mouse assay is the accepted standard for the detection of botulinum toxin.  
This assay requires the use of many animals, and requires several days to determine the 
amount and type of toxin present (1, 47, 53, 59, 118, 181).  Due to the potency of the 
botulinum neurotoxins, it is important to rapidly detect and differentiate between the 
toxins in food, clinical or environmental samples.  A rapid, sensitive and specific assay is 
needed for the detection and differentiation of botulinum neurotoxins. 
The ability to rapidly and accurately detect contaminated food and water would 
serve as a preventive measure and aid those involved in public health, quality control 
specialists and possibly first responders in the reduction of the spread of disease.   
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MATERIALS AND METHODS 
 
Bacterial strains 
 
 Vibrio cholerae Pacini 569B ATCC 25870 and Vibrio cholerae Pacini El Tor 
ATCC 39050 were obtained from the American Type Culture Collection (Manassas, 
VA).  Vibrio cholerae O1 El Tor Inaba was obtained from the Centers for Disease 
Control and Prevention (CDC, Atlanta, GA).  Bacteria were suspended in tryptic soy 
broth with 20% glycerol (Remel, Lenexa, KA) and stored in a -80°C freezer until needed. 
Media and Culture Conditions 
 Stock cultures.  All cultures were grown on tryptic soy agar plates (TSA, Remel) 
for 18 hours in a 37°C incubator and serially diluted in 0.01 M phosphate-buffered saline, 
0.85% NaCl, pH 7.4 (PBS) for use in assays. 
 Enrichment and selective media.  Alkaline peptone broth (1% NaCl, 1% peptone , 
pH 8.5) was used for the enrichment of all V. cholerae isolates from seawater and oyster 
matrices.  Casamino acids yeast extract medium (CAYE,  3% casamino acids, 0.3% yeast 
extract, 0.05% K2HPO4, pH 7.0, CAYE with 0.2% glucose, Instant Ocean (Aquarium 
Systems, Inc. Mentor, OH.), Salt water culture medium (0.05 % peptone, 0.03 % yeast 
extract, 0.03 % glycerol, 0.01 % CaCO3), Salt water culture medium with 0.2% glucose, 
Salt water culture medium made in Instant Ocean and Salt water culture medium with 
0.2% glucose made in Instant Ocean were used in the development of enrichment assays 
(108). 
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 Thiosulfate Citrate Bile Salts agar (TCBS, Becton Dickinson & Co., Sparks, MD) 
was used for the selective plating of V. cholerae.  Plates were grown at 37° C in an 
incubator for 18 hours.  Suspect yellow colonies were tested using API 20E (Biomerieux, 
Durham, NC) and PCR for confirmation. 
Toxins 
 Lyophilized cholera toxin beta subunit (CT-B) and cholera toxin (CT) were 
purchased from Sigma Chemical Co. (Saint Louis, MO) and reconstituted in 0.1M 
phosphate buffered saline, pH 7.4.  Two botulinum toxoids were provided by the CDC.  
Type-A botulinal toxoid was at a 1:10,000 dilution and type-B botulinal toxoid at a 
1:1,000 dilution. 
Gangliosides 
 The lyophilized gangliosides GM1, GD1b and GT1b were purchased from Sigma 
Chemical Co.  The GM1 was reconstituted in PBS. 
Liposomes 
 Liposomes were made to specification by Dr. Anup Singh at the Sandia National 
Laboratories (Livermore, CA). The liposomes (Figure 9) were composed of L-α-
distearroylphosphatidylcholine (DSPC), cholesterol, Alexa-DHPE (Alexafluor 647-1,2-
dihexadecanoyl-sn –glycerol-3-phospoethanolamine, Molecular Probes, Eugene, Oregon) 
and GT1b (Sigma Chemical Co.) (151).  The mole ratio used was 42.5:42.5:10:5 
(DSPC/cholesterol/Alexa Fluor/GT1b) (156). 
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FIGURE 9. Liposome construct (156). 
 
Antibodies and Labeling 
 Sources. Lyophilized rabbit anti-cholera toxin beta subunit antibody was 
purchased from Biogenesis (Kingston, NH) and reconstituted in PBS.  Lyophilized rabbit 
anti-V. cholerae antibody was purchased from Difco (Sparks, MD).  Lyophilized rabbit 
anti-botulinum toxin antibody was purchased from Accurate Chemical and Scientific 
Corporation (Westbury, NY) and reconstituted in PBS.  Goat anti-botulinum type A, 
rabbit anti-botulinum type B and goat anti-botulinum type B antibodies were a gift from 
the CDC.  Affinity purified peroxidase goat anti-rabbit IgG was purchased from 
Kirkegaard & Perry Laboratories Inc. (KPL, Gaithersburg, MD).  Goat anti-rabbit IgG 
conjugated to alkaline phosphatase was purchased from Sigma Chemical Co.  Affinity 
purified peroxidase rabbit anti-goat IgG was purchased from Jackson Immunologicals 
(West Grove, PA). 
 Cyanine 5 labeling.  Cholera toxin and botulinum toxin antibodies were labeled 
directly with the cyanine 5 fluorophore (FluoroLink Cy5 Reactive Dye 5-pack Amersham 
Biosciences, Piscataway, NJ).  Labeling was performed according to the protocol 
Ganglioside
Fluorescein-lipid
Toxin
Antibody
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described previously by Demarco et al. (37).  The antibody to be conjugated was diluted 
to 1mg/ml in 500 µl of conjugation buffer (0.1 M carbonate-bicarbonate buffer, pH 9.3).  
The antibody solution was added to the cyanine 5 dye pack vial.  The dye pack vial was 
placed in the original foil packaging and placed at 4°C for 18 hours. Free dye and labeled 
antibody were separated by filtration on a Bio-Gel P10 column (exclusion limit of 1,500 
to 20,000 Da; Bio-Rad, Hercules, CA).  A 10 ml bed volume was poured and equilibrated 
with PBS-0.1% sodium azide.  Labeled-antibody fractions were collected and the molar 
concentration of the labeled antibody was determined using a DU®-64 spectrophotometer 
(Beckman, Fullerton, CA) set at 280 nm and 650 nm.  Cy5 labeled antibodies were stored 
at 4°C until needed. 
 Biotin labeling.  Antibodies were labeled with biotin using succinimidyl-6-
(biotinamido) hexanoate (EZ-Link NHS-LC-Biotin; Pierce, Rockford, IL).  Labeling was 
performed according to the protocol described previously by DeMarco et al. (37).  One 
mg of EZ-Link NHS-LC-Biotin was dissolved in 1 ml of N,N-dimethylformamide 
(DMF); 75 µl of this solution was added to 425 µl of antibody that had been dissolved in 
0.1 M sodium carbonate, pH 8.5, at a concentration of 2 mg/ml.  The solution was then 
placed on ice for 2 hours.   Free biotin and labeled antibody were separated by filtration 
on a Bio-Gel P10 column.  Labeled-antibody fractions were collected in half ml fractions 
and the protein concentration of the labeled antibody was determined using a DU®-64 
spectrophotometer set at 280 nm.  Biotinylated labeled antibodies were stored at 4°C 
until needed. 
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Viable Counts  
 Cells were resuspended in 0.1 M PBS, pH 7.4 (100 dilution).  Ten-fold serial 
dilutions were made, 10-1 to 10-7.  Nine hundred micrliters of sterile PBS, pH 7.4, in 
sterile microfuge tubes was used as the diluent.  One-hundred microliters of appropriate 
dilutions (usually 10-5, 10-6, 10-7) were duplicate plated onto TSA and incubated at 37°C 
for 18 hours. 
Oysters 
 Unshelled oysters processed by Hilton’s Willapoint (South Bend, WA) were 
purchased from Publix (Lakeland, FL).  Live oysters were harvested from the northwest 
side of the Gandy Bridge at Tampa Bay, Fl. (Figure 10).  Live oysters were collected and 
immediately placed on ice.  They were transported back to the laboratory within an hour 
and placed in a 10 gallon tank containing Instant Ocean (20 ppt NaCl) as described by 
Murphree and Tamplin (111). 
 50  
 
FIGURE 10. Map of Tampa Bay, Florida.  Live oysters were harvested during low tide 
from the northwest side of the Gandy Bridge on the St. Petersburg side of the Tampa 
Bay. 
Toxin Assays 
 Bicinchoninic acid  protein assay.  Fifty parts of BCA reagent A (Sigma 
Chemical Co.) were mixed with 1 part BCA reagent B (Sigma Chemical Co.) to make the 
working reagent.  A standard curve was made using Bovine Serum Albumum (BSA, 
Fisher, Pittsburgh, PA).  For each concentration, BSA was mixed with PBS to a final 
volume of 50 µl.  One ml of the working reagent was added to each BSA concentration 
and incubated at room temperature for 1 hour.  At the same time CT-β was serially 
diluted and then one ml of working reagent was added and incubated at room temperature 
for 1 hour.  The absorptions were determined using a DU®-64 spectrophotometer set at 
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562nm.  The concentration of the protein was determined by extrapolating from the 
standard curve line. 
 SDS-PAGE.  12% Bis Tris precast gels purchased from Invitrogen (Carlsbad, CA) 
were used.  Twenty microliters of the protein sample, 10 µl of sample buffer (Invitrogen, 
Carlsbad, CA), 4 µl of reducing agent (Invitrogen) and 6 µl of DI water were mixed and 
heated at 70°C for 10 minutes.  Twenty microliters of each protein sample mixture was 
used per well.  One well contained 10 µl of the Novex Color Marker 12 (Sigma Chemical 
Co.).  MES-DES running buffer (Invitrogen) was used and the gel was electrophoresed at 
200V for 40 minutes.  The gel was then stained with Coomassie Blue R250 (Sigma 
Chemical Co.) for one hour.  The gel was destained with a 7.5% methanol, 10% acetic 
acid solution for 30 minutes and then placed in DI water for 18 hours. 
 Western blot.  An SDS-PAGE gel was removed from the gel box and transferred 
to a nitrocellulose membrane at 14V, 4° for 18 hours using Towbin buffer, pH 8.3 (173).  
The membrane was removed and incubated on a shaker with 5% skim milk/PBS, pH 7.4, 
containing 0.1% Tween 20 (PBST, pH 7.4) at 24°C for 10 minutes.  The gel was rinsed 
once with PBST and then incubated with the primary antibody, polyclonal anti-CT-β 
rabbit (Biogenesis) at a 1:500 dilution for one hour at 24°C.  This was followed by three 
45 second washes with 10 mM EDTA/PBS (pH 8.5).  The membrane was rinsed three 
times with PBST for 20 seconds each and then incubated with the secondary antibody, 
goat anti-rabbit IgG conjugated to alkaline phosphatase at a 1:5,000 dilution for an hour 
at 24°C.  This was followed by three 30 second washed with PBST.  Substrate (50 ml 
borate buffer, ph 9.7, 13 mg o-dianisidine, 13 mg β-napthyl acid phosphate) was added 
and the membrane was kept in the dark until bands appeared. 
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 Ganglioside-based ELISA.  All volumes were at 100 µl and all incubations were 
at 24°C unless otherwise noted.  Ganglioside was dissolved in PBS at a concentration of 
1.5 µg/ml.  One hundred microliters were added to the wells of a 96-well Nunc Maxi 
Sorp microtitre plate and incubated at 37°C for 18 hours.  This mixture was aspirated and 
wells were washed once with PBST.  Blocking buffer (PBS, 2 mg/ml casein, 2 mg/ml 
BSA) was added and incubated at 24°C for 30 minutes.  This mixture was aspirated and 
wells were washed once with PBST.  The antigens were added into their respective wells 
and incubated for 10 minutes.  This solution was aspirated and wells were washed three 
times with PBST.  Polyclonal antibody at a concentration of 10 µg/ml was added to each 
well and incubated for 30 minutes.  This mixture was aspirated and wells were washed 
three times with PBST.  Horseradish peroxidase-labeled secondary antibody, anti-rabbit 
IgG or anti-goat IgG (KPL) was added to each well at a 1:500 dilution and incubated for 
30 minutes.  This mixture was aspirated and wells were washed three times with PBST.  
QuantaBlue substrate (Pierce Biotechnology, Rockford, IL) was added and incubated for 
25 minutes.  QuantaBlue stop solution (Pierce Biotechnology) was added and the relative 
fluorescence was determined at 325 nm excitation and 420 nm emission with a Spectra 
Max Gemini XS fluorometer (Molecular Devices, Sunnyvale, CA).  A signal to noise 
ratio of 2 was positive detection. 
 Indirect ELISA.  All volumes were at 100 µl and all incubations were at 24°C 
unless otherwise noted.  Serial dilutions of protein were made in sterile 0.01 M PBS with 
0.1% BSA, pH 7.4.  Protein was added to the wells of a 96-well Nunc Maxi Sorp 
microtitre plate and incubated at 4°C for 18 hours.  This mixture was aspirated and wells 
were washed once with PBST.  Blocking buffer was added and incubated at 24°C for 30 
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minutes.  This solution was aspirated and wells were washed once with PBST.  Primary 
antibody at 10 µg/ml was added to each well and incubated for 30 minutes.  This mixture 
was aspirated and wells were washed three times with PBST.  Horseradish peroxidase-
labeled secondary antibody, anti-rabbit IgG or anti-goat IgG was added to each well at a 
1:500 dilution and incubated for 30 min.  This mixture was aspirated and wells were 
washed three times with PBST.  After washing, QuantaBlue substrate (Pierce 
Biotechnology) was added and incubated for 25 minutes.  QuantaBlue stop solution 
(Pierce Biotechnology) was added and the relative fluorescence was determined at 325 
nm excitation and 420 nm emission with a Spectra Max Gemini XS fluorometer 
(Molecular Devices).  A signal to noise ratio of 2 was positive detection. 
 Toxin induction.  Vibrio cholerae O1 569B ATCC 25870, Vibrio cholerae O1 El 
Tor ATCC 39050 and Vibrio cholerae O1 El Tor CDC were grown on TSA.  Strains 
were induced to produce CT by following the protocol of Minami et al. (108).  Ten ml of 
modified CAYE broth were placed into sterile 100 mm petri dishes.  Each dish was 
inoculated with two colonies from each strain.  After stationary incubation for 18 hours at 
30°C, a loopful of the culture was transferred to a new petri dish containing 10 ml of the 
modified CAYE medium with 0.2% glucose.  Salt water culture medium, Salt water 
culture medium made in Instant Ocean (Aquarium Systems) and CAYE made in Instant 
Ocean were also used as enrichment media for the production of CT.  This culture was 
incubated under stationary conditions for 18 hours at 30°C.  Five ml of each culture was 
stored at 4°C and 5 ml was centrifuged (1,600 × g, 30 min, 4°C).  The supernatant fluids 
were filtered through sterile 0.22 µm-pore-size membrane filters.  CT in the filtered 
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supernatant fluid was detected using the Analyte 2000 (Research International) and an 
ELISA.  
 Toxin spiked oysters.  Four grams of oyster (Hilton’s Willapoint, South Bend, 
WA) and 36 ml of Alkaline Peptone Water (APW, pH 8.5) were added into a 50 ml 
conical tube and spiked with CT (168).  The sample was homogenated for 90 seconds at 
the highest speed using a PowerGen 125 homogenizer (Fisher) allowed to settle at 24°C 
for 15 minutes and then separated by filtration on a Bio-Gel P10 column.  A 4 ml bed 
volume was poured and equilibrated with PBS with 0.1% sodium azide.  Ten oyster 
fractions were collected in 500 ul volumes.  The CT was detected using the Analyte 2000 
(Research International) and an ELISA. 
 Tank inoculation.  A 10 gallon aquarium tank with 10 L of medium was set up 
and the liquid was recirculated with an AquaClear aquarium pump (Wal-Mart) (Figure 
11).  The temperature in the tank was maintained at varying temperatures with a Visi-
Therm Automatic Aquarium Heater (Wal-Mart).  On day one, oysters harvested from the 
Tampa Bay were introduced into the tank and allowed to sit for 24 hours, these were 
designated the control oysters, tc.  On day two, the tank was inoculated with V. cholerae 
569B ATCC 25870 to a final concentration of 104 cfu/ml and the oysters collected prior 
to inoculation were designated t0.  Beginning on day two, oyster and broth medium 
samples were collected at the following time intervals: t0, t6, t12, t24, t48 and t72 hours. 
 Following the method of Murphree and Tamplin, ten oysters from each tank were 
scrubbed and their meat pooled (111).  The meat was homogenized 1:1 in PBS followed 
by serial dilution in PBS.  A five tube MPN was prepared by enriching dilutions of oyster 
homogenate or tank medium in APW (pH 8.5) at 42°C for 6 hours in a water bath.  Each 
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tube in the MPN series was then streaked onto TCBS (Difco) (41).  Plates were incubated 
at 37° C for 18 hours.  Suspect V. cholerae isolates were confirmed using API 20E and 
PCR.  
 
 
    FIGURE 11.  Tank set-up. 
 
API 20E Identification   
 Yellow colonies that were 2-3 mm in diameter, gram negative rods and oxidase 
positive were resuspended in PBS and identified using the API 20E (Biomerieux, 
Durham, NC).  Colonies identified as V. cholerae were further confirmed using PCR.  
PCR 
 PCR targeted two genes for the identification of Vibrio cholerae:  the 564 base 
pair region of the cholera toxin A subunit (ctxA) and the 300 base pair region of the 16S-
23S rRNA intergenic spacer region (its).  Primers were made by IDT (Coralville, IA) and 
their sequences are listed in Table 5.  The forward and reverse primers were diluted to a 
10 µm concentration.  Each 50 µl reaction volume contained the following: 1X PCR  
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TABLE 5. PCR primers for identification of Vibrio cholerae. 
Target  Sequence            Amplicon        Reference 
               size (bp) 
 
 
ctxA  F 5’ CGG GCA GAT TCT AGA CCT CCT G 3’  564  48 
  R 5’ CGA TGA TCT TGG AGC ATT CCC AC 3’  
its  F 5’ TTA AGC ATT TTC TCT GAG AAT G 3’ 300  21 
  R 5’ AGT CAC TTA ACC ATA CAA CCC G 3’ 
 
 
buffer, 200 µM each of dNTP mixture, 0.25 µM of the forward and reverse primer, 2 µl 
of whole V. cholerae cells resuspended in sterile DI water, 2.5U of TaKaRa ExTaq 
polymerase (TaKaRa, Shuzo, Otsu, Japan) and 37.25 µl sterile water.  Samples were run 
on a Bio-Rad iCycler (Hercules, CA) with the following conditions: 95° C for 2 minutes; 
30 cycles of 95°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minute; and extension 
at 72°C for 10 minutes.  PCR products were visualized by 1% agarose (Amresco Inc., 
Solon, OH) gel electrophoresis.  The volume per lane was 8 µl of each PCR reaction 
mixed with 2µl of loading dye (Bio-Rad, Hercules, CA).  Five microliters of each 
PCR/dye mixture was electrophoresed on a 1.5 % agarose gel.  A 1 kb PCR marker 
(Promega, Madison, WI) was used.  Amplicon bands were visualized using GelStar 
nucleic acid stain (BioWhittaker Molecular Applications, Rockland, MD) at a 
concentration of 3 µl stain/100 ml agarose in TBE buffer and a transilluminator.      
Ganglioside-Based Biosensor Assay for the Detection of Cholera Toxin 
 Analyte 2000 biosensor.  The Analyte 2000 (Research International) is a fiber-
optic biosensor that utilizes the properties of an evanescent wave in conjunction with a 
fluoroimmunoassays to detect a wide variety of molecules (Figure 12).  Utilizing four 
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different fiber-optic probes and a single wavelength, the Analyte 2000 can analyze up to 
four channels simultaneously.  Results are produced in near real-time, approximately 20 
minutes with previously prepared waveguides.  The Analyte 2000 can assay for target 
analyte in dirty matrices (37, 38, 39, 86, 171).                         
 
 
FIGURE 12.  Analyte 2000 evanescent wave, fiber-optic biosensor. 
  
 Fiber preparation.  A polystyrene waveguide (Research International) was 
sonicated for 30 seconds in isopropanol.  The waveguide was rinsed in DI water and 
black ink was placed on the distal end of the waveguide to prevent the escape of light.  
After the paint dried, the waveguide was added to a glass capillary tube to form a reaction 
chamber.  The waveguide was incubated with 1.5 µg/ml of GM1 in PBS and incubated 
18 h at 37°C.  The waveguide was removed from the glass capillary tube and placed into 
an Analyte 2000 cuvette as shown in Figure 13.  The waveguide was rinsed with 1 ml of 
PBST.  
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           Cuvette                                                 Waveguide                      Cuvette Cap 
      Assay Chamber 
FIGURE 13.  Assembly of Analyte 2000 cuvette and polystyrene waveguide used in 
biosensor assays. 
  
 Background readings.  Waveguides were rinsed with 1 ml PBST, and then three 
background readings were taken by repeating the following steps:  each waveguide was 
incubated for 5 minutes with 200 µl Cy-5 labeled anti-CT- β-subunit IgG (10 µg/ml) in 
blocking buffer (2mg/ml casein, 2 mg/ml BSA in PBS), followed two 1 ml PBST rinses.  
The laser was turned on and the value, in picoAmperes (pA), was recorded after the final 
rinse.  For each reading, the value recorded after the last PBST rinse was designated the 
baseline reading.  The pA value for each baseline reading was subtracted from the 
subsequent baseline reading, and this calculated value was designated as the change in 
previous signal for baseline readings 2-4.  The average of change in previous signal for 
the baseline readings was calculated. The detection limit was calculated as three times the 
standard deviation (SD) of the change in previous signal for the baseline readings plus the 
average of change in previous signal.  When samples were tested, each previous sample 
reading was subtracted from the next sample reading. 
 Sample assay.  Figure 14 illustrates the immunoassay used with the Analyte 2000.  
Assays were performed by adding 1 ml of sample to the reaction chamber containing the 
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fiber waveguide and incubating at 24°C for 10 minutes.  The sample was rinsed with 1 ml 
PBST and the waveguide was incubated for 5 minutes at 24°C with 200 µl Cy5 anti-CT- 
B-subunit IgG in blocking buffer.  The waveguide was rinsed twice with PBST and the 
laser was turned on.  The signal was recorded in pA.  The change in signal (∆pA) was 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14.  Illustration of sandwich immunoassay utilized with Analyte 2000.  The 
target antigen is captured by a bound biomolecule in a standard immunoassay.  The 
captured antigen is detected by a Cy5-labeled detection antibody. 
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calculated as the value of the sample reading after the second rinse minus the value of the 
previous sample reading.  In order to account for variation among each waveguide, the 
values were normalized by using the following equation (85).   
∆pA value for sample being tested     × 100 
∆pA value for 100 ng/ml CT 
 
A sample was considered positive if the change in signal (∆pA) was above the limit of 
detection and the normalized value was above zero. A standard curve was generated 
using known CT concentrations.  CT concentrations of the samples were determined by 
extrapolation from the CT standard curve. 
 The assay for signal amplification follows the same biosensor protocol with the 
following exception.  The secondary antibody, Cy5 conjugated anti-rabbit IgG, was 
incubated with the primary antibody, anti-CT antibody, in a 1:2 ratio, respectively, to a 
final protein concentration of 10 µg/ml. The antibodies were incubated at 24°C for 5 min 
before incubation on the waveguide.    
 Cholera toxin standard preparation.  The stock solution was prepared by diluting 
CT to 100 ng/ml in PBS containing 0.1% BSA.  This was serially diluted tenfold in PBS-
BSA 0.1 %.   
Liposome-Based Biosensor Assay for the Detection of Botulinum Toxin 
 Fiber preparation.  Waveguides were prepared as previously described.  The 
waveguide was incubated in the glass capillary reaction chamber with 100 µl of 100 
µg/ml streptavidin solution prepared in PBS for 18 hours at 4°C.  The waveguide was 
removed from the glass capillary tube and placed into an Analyte 2000 cuvette as shown 
in Figure 13.  The waveguide was rinsed with 5 ml PBST to remove any unbound 
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streptavidin.  One hundred microliters of 100 µg/ml of biotinylated polyclonal anti-
botulinum toxin was prepared in PBS and this was incubated on the waveguide for one 
hour at 24°C.  Following incubation with the biotinylated antibody, the waveguide was 
rinsed with 1 ml of PBST. 
 Background readings.  Fibers were rinsed with 1 ml PBST, and then three 
background readings were taken by repeating the following steps:  each waveguide was 
incubated for 5 minutes at 24°C with 200 µl of liposome at varying dilutions followed 
two 1 ml PBST rinses.  The laser was turned on and the value, in picoAmperes (pA), was 
recorded after the final rinse.  For each reading, the value recorded after the last rinse was 
the baseline reading.  The standard deviation was calculated as previously described.  
 Sample assay.  Assays were performed by adding 1 ml of sample to the reaction 
chamber containing the fiber waveguide and incubating at 24°C for 10 minutes.  The 
sample was rinsed with 1 ml PBST and the waveguide was incubated with 200 µl of 
liposome for 5 minutes at 24°C.  The waveguide was rinsed twice with PBST.  The laser 
was turned on and the signal was recorded in pA.  The change in signal was calculated as 
previously described.  A sample was considered positive if the change in signal was 
above the limit of detection and the normalized value was above zero.  
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RESULTS 
Biosensor Immunoassay Development for the Detection of Cholera Toxin 
Cholera Toxin Purity   
 CT-B and CT purchased from Sigma were assayed for the presence of other 
proteins.  An SDS-PAGE (Figure 15) and a Western blot (Figure 16) were performed to 
assess protein purity.  The cholera toxin is composed of two subunits with molecular 
weights of 27.2 kD A subunit and 11.6 kD B subunit.  CT-B is a polymerized form of the 
B subunit that, when subjected to the reducing conditions of an SDS-PAGE, should 
dissociate into CT-β momomers.  CT- β monomers produced a band at approximately 
11.5 kD corresponding to the molecular weight of the B subunit.  There were no visible 
band on either the SDS-PAGE or the Western blot that correlated to the molecular weight 
of subunit A.  The holotoxin has an A to B ratio of 1:5 and, therefore, it is possible that 
there was a smaller concentration of the A subunit.  The polyclonal anti-CT-B antibody 
used for the Western would not detect the A subunit.  The holotoxin dissociated when 
subjected to the reducing agent used in the SDS-PAGE.  Therefore, the presence of a 
band with approximately the same molecular weight corresponding to the B subunit, 11.5 
kD, on both the gel and membrane (Figure 15 and 16) and the lack of any other protein 
bands reaffirmed that the commercially purchased toxins were not contaminated. 
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FIGURE 15. SDS-PAGE of CT and CT-B.  Lane 1, 10 ng CT; Lane 2, 10 ng CT-B; Lane 
3, marker.  The bands visible in lanes 1 and 2 corresponded to the molecular weight of  
CT- B. 
 
 
 
 
 
 
      
 
 
 
 
 
 
FIGURE 16. Western blot of CT and CT- B.  Lane 1, 10 ng CT; Lane 2, 10 ng CT- B; 
Lane 3, marker.  Filter was probed with anti-CT- B antibody. 
14.4 kD
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1                    2                  3
1                        2                        3
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 BCA protein assay.  A BCA protein assay was done in order to determine if the 
concentration of the CT- B protein listed on the Sigma label was accurate (Table 6).  The 
concentration of the protein was listed at 1 mg/ml. 
 
TABLE 6.  Extrapolated CT-B concentrations from BCA standard curve. 
Protein concentration Absorbance @ 562 nm Extrapolated concentration  
  
 0 mg/ml BSA 0 - 
 0.2 mg/ml BSA 0.165  
 0.4 mg/ml BSA 0.366 - 
 0.6 mg/ml BSA 0.513 - 
 0.8 mg/ml BSA 0.655 - 
 1 mg/ml BSA 0.780 - 
 0.2 mg/ml CT-B 0.188 0.216 mg/ml CT-B 
 0.6 mg/ml CT-B 0.443 0.538 mg/ml CT-B 
 
 
 The correlation coefficient (r) of the line was 0.997.  It was determined that 
dilutions made from this commercial source of protein would correspond with the 
expected calculated value of that dilution.  The label concentration of protein in Sigma 
CT- B was considered accurate. 
Comparison of Affinity and Specificity of GM1 and Polyclonal Antibody Binding to V. 
cholerae Whole Cells and Toxin   
 A sandwich ELISA using GM1 for capture and anti-CT- B for detection was used 
to test the affinity of the ganglioside GM1 and the anti-CT- B antibody binding to V. 
cholerae serotypes O1 and O139 and to CT- B (Figure 17). Two sets of ten-fold serial 
dilutions were made for both V. cholerae O1 and V. cholerae O139.  One set of dilutions 
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was boiled for 10 minutes, whereas the other set was composed of viable cells.  Ten-fold 
serial dilutions were also made of CT-B (initial concentration at 1 mg/ml).   
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FIGURE 17. Sandwich ELISA with GM1 as capture molecule and anti-CT-B antibody as 
detection molecule for detection of CT- B and V. cholerae serotypes.  Tenfold dilutions 
of V. cholerae serotype O1 (▪; 1.62 x 109 cfu/ml), V. cholerae serotype O1 boiled 
(▲;1.62 x 109 cfu/ml), V. cholerae serotype O139 (■; 7.3 x 108 cfu/ml),  V. cholerae 
serotype O139 boiled (x; 7.3 x 108 cfu/ml) and CT- β (♦; 1mg/ml) were done in duplicate.  
Error bars (⊥) indicate the standard deviation of the means. 
 
 When the GM1 was used for capture and the anti-CT- B antibody was used for 
detection, there is no cross-reactivity to cells.  The sandwich ELISA was capable of 
detecting CT-B at a dilution of 10-5 which corresponds to concentration of 10 ng/ml.  The 
sandwich ELISA shows no reactivity to V. cholerae cells.  The cells themselves will not 
be a source of false positives, they must produce CT- B for positive detection.    
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CT Standard Curve   
 A standard curve was generated using the sandwich ELISA as previously 
described (Figure 18).  Assays using the Analyte 2000 (Figure 19) are also shown. GM1-
coated wells or waveguides were prepared at a concentration of 1.5 µg/ml.  Serial 
dilutions of CT- β were added to the wells or waveguides and incubated for 10 minutes.  
After washing, anti-CT- B antibody was added to wells or waveguides.  Antibody was 
detected using secondary antibody for ELISA or by a direct Cy5 label for the Analyte 
2000.  Sample values for the Analyte 2000 were normalized (as previously described) 
using 100 ng/ml as the standard.  For all ELISA assays, a signal to noise value greater 
than 2 was treated as a positive signal.  The sensitivity of the ELISA was approximately 
0.625 ng/ml CT-B. 
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FIGURE 18. Mean value for ELISA CT-B standard curve.  Sandwich ELISA with GM1 
as capture molecule and anti-CT-B antibody as detection molecule.  Mean value for three 
separate assays. 
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FIGURE 19.  Analyte 2000 normalized standard curve of CT-B.  Mean normalized 
values for 21 waveguides.   
      
 The average normalized values and standard deviations for the three serial 
dilutions of 1 mg/ml CT-B are listed in Table 7.  The limit of detection for the Analyte 
2000 assay was 1 ng/ml.  The Analyte 2000 assay has a greater dynamic range of 
detection.  It detects 1 ng/ml to 100 ng/ml of CT-B while the ELISA becomes saturated at 
CT-B of 2.5 ng/ml. 
 
TABLE 7.  Average normalized ∆pA values and standard deviations for CT-B standard 
curve using the Analyte 2000. 
 
CT-B concentration Average normalized value Standard deviation 
 
 0.1 ng/ml 1.6 1.53 
 1 ng/ml 4.2 0.95 
 10 ng/ml 24.8 3.83 
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Sensitivity of Antibody Versus Ganglioside as Capture Molecule   
 An Analyte 2000 assay comparison was done using ant-CT-B antibody as the 
capture molecule versus the ganglioside, GM1, as the capture molecule.  The assay was 
performed in order to determine if one of the biomolecules was more effective at 
capturing CT- B.  Two waveguides were incubated with GM1 for 18 hours at 1.5 µg/ml 
in a 37°C incubator.  Two waveguides were incubated with 100 µl of 100 µg/ml 
streptavidin for 18 hours at 4°C.  The following day the waveguides were rinsed with 5 
ml PBST and 100 µl of 50 µg/ml of biotin-labeled anti-CT- β antibody was incubated 
with the two waveguides containing streptavidin at 24° C for one hour.  The standard 
biosensor assay protocol using Cy5-anti-CT- B antibody for detection was followed.  
Figure 20 illustrates that the ganglioside GM1 as a capture molecule produced the same 
levels of detection sensitivity as the anti-CT- B antibody:  1 ng/ml. 
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FIGURE 20. Comparison of anti-CT- B antibody (♦) versus GM1 ganglioside-based (▪) 
capture assay using the Analyte 2000.  Cy5-anti-CT- B antibody was used for detection 
in both assays.  Error bars are present, but not visible with some data points because they 
are so small.        
Signal Amplification 
 A secondary antibody that would bind the Fc portion of the anti-CT-β antibody 
was used to amplify the pA signal of the Analyte assay (Figure 21).  Amplification of the 
signal may allow detection of lower concentrations of CT- B.   The secondary antibody, 
Cy5-labeled anti-rabbit-IgG, was preincubated with the primary antibody (anti-CT- B) at 
a ratio of 1:2 prior to incubation on each waveguide.  The same biosensor assay protocol 
was followed, but the antibody mixture was used as the detection antibody. 
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FIGURE 21.  Comparison of biosensor assay using Cy5-anti-CT- B antibody (▪) or a 
mixture of anti-CT- B antibody and Cy5-anti-rabbit IgG (♦) as the detection reagent. 
 
 The average normalized ∆pA values and standard deviations for the three serial 
dilutions of 1 mg/ml CT- B are listed Table 8.  The trends in variability in normalized 
values for signal amplification were the same as those seen in the CT standard curve.  
Adding a secondary antibody did not increase the sensitivity of the assay.  The limit of 
detection for the assay was determined to be the same as the assay with no signal 
amplification:  1 ng/ml CT-B. 
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TABLE 8. Average normalized ∆pA values and standard deviations for signal 
amplification using the Analyte 2000. 
 CT-B concentration Average normalized value Standard deviation 
 0.1 ng/ml 0.3 0.3 
 1 ng/ml 2.3 0.8 
 10 ng/ml 20.0 5.1 
 
  
 The signal amplification did not cause an increase in sensitivity of the assay.  The 
average normalized values were lower for signal amplification than with a primary 
antibody only (Table 7 and 8).  Figure 21 demonstrates that there is no advantage to using 
a secondary antibody. 
Toxin Induction   
 ELISA and Analyte 2000 utilizing CT.  Vibrio cholerae cells produce the 
holotoxin CT, not just CT-B.  In previous ELISA and Analyte 2000 assays, a 
commercially modified CT-B was used to generate data.  There was a concern that 
ELISA and biosensor results would change when testing the holotoxin, CT.  With the 
ELISA, it became necessary to lower the anti-CT- B antibody concentration to 310 
ng/ml.  The concentration used in previously reported assays was 10 µg/ml, but the range 
of detection was low (0.1-5 ng/ml) because the antibody saturated the signal.  The 
detection antibody concentration remained 10 µg/ml for the Analyte 2000 assays.  
Detection of CT instead of CT- B produced results with a sensitivity similar to the one 
obtained with the ELISA (Figure 22) and the Analyte 2000 (Figure 23):  1 ng/ml.   
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FIGURE 22. ELISA values for CT standard curve assay.  Standard curve values are the 
mean of four assays.   
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FIGURE 23.  Standard curve for CT using Analyte 2000.  The ∆pA values are the mean 
from eight waveguides. 
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 The average normalized ∆pA values were higher and the standard deviations were 
lower when CT was utilized in the assay instead of CT-B (Table 9).  However, the limit 
of detection when using CT was the same as when testing CT- B: 1 ng/ml. 
 
TABLE 9.  Average normalized ∆pA values and standard deviations for CT standard 
curve using the Analyte 2000. 
  
 CT concentration Average normalized value Standard deviation 
 
 0.1 ng/ml  2.5 1.2 
 1 ng/ml 5.9 1.4 
 10 ng/ml 28.2 3.9 
 
 
 CAYE as induction medium.  Using the Miniami et al. protocol, three strains of V. 
cholerae were induced in vitro to produce cholera toxin:  Vibrio cholerae Pacini 569B 
ATCC 25870, Vibrio cholerae Pacini El Tor ATCC 39050 and Vibrio cholerae O1 El 
Tor Inaba CDC (108).  Cholera toxin was detected by ELISA and Analyte 2000 without 
signal amplification (Table 10). 
 Cell counts of 108 cfu/ml or higher were needed to induce CT production.  Vibrio 
cholerae O1 Classical 569B ATCC 25870 is considered to be the ideal CT producing 
strain (44).  Based on the values in Table 10, this organism produced the greatest amount 
of CT.  Both V. cholerae El Tor strains produced lower levels of CT and were not ideal 
toxin producers.  Signal saturation occurred at approximate CT concentrations of 5 ng/ml 
in ELISAs for CT.  Analyte 2000 normalized values greater than 5.9 (Table 9), the limit 
of detection for 1 ng/ml from the CT standard curve assay, were treated as positives.   
 74  
V. cholerae O1 Classical 569B ATCC 25870 was the only strain that had positive values 
for all of the assays utilizing both methods of detection.  High concentrations (>108 
cfu/ml) of V. cholerae O1 El Tor ATCC 39050 never produced positive signals with the 
Analyte 2000 and had 60% (3/5) positive ELISA tests.  The V. cholerae O1 El Tor 
(received from the CDC) was not any more efficient at CT production than the ATCC El 
Tor strain.  The CDC El Tor strain never generated positive signals with the Analyte 
2000 and had 80% (4/5) positive ELISA tests for CT production.  The concentration of 
primary antibody used for an ELISA was 310 ng/ml, while 10 µg/ml of detection 
antibody was used with the Analyte 2000.  The difference in antibody concentration 
could account for positive signals generated with the ELISA and not the Analyte 2000.  
Based on the higher values shown for CT production in Table 10, V. cholerae O1 
Classical 569B ATCC 25870 was selected as the strain to use in future induction assays. 
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TABLE 10.  Cholera toxin induction values utilizing an ELISA and the Analyte 2000. 
  
 Viable count Analyte 2000 ELISA 
  normalized value signal to noise ratio 
 
Assay 1  
V. cholerae O1 El Tor (ATCC 39050) 5.9 x 108 cfu/ml 1.6 3.7 
V. cholerae O1 El Tor (CDC) 3.0 x 109 cfu/ml 3.4 3.9 
V. cholerae O1 Classical 569B  4.2 x 109 cfu/ml 53.5 4 
(ATCC 25870) 
 
Assay 2 
V. cholerae O1 El Tor (ATCC 39050) 1.85 x 109 cfu/ml 0.4 3.4 
V. cholerae O1 El Tor (CDC) 1.36 x 109 cfu/ml 1.6 4.4 
V. cholerae O1 Classical 569B 3.9 x 109 cfu/ml 51.3 4.4 
(ATCC 25870) 
 
Assay 3 
V. cholerae O1 El Tor (ATCC 39050)  2.89 x 109 cfu/ml 0.7 2.6 
V. cholerae O1 El Tor (CDC)  2.95 x 109 cfu/ml 2.7 3.8 
V. cholerae O1 Classical 569B 1.07 x 1010 cfu/ml 65.4 5.4 
(ATCC 25870) 
 
Assay 4 
V. cholerae O1 El Tor (ATCC 39050)  2.02 x 109 cfu/ml 0.8 1.0 
V. cholerae O1 El Tor (CDC) 8.9 x 108 cfu/ml 2.2 1.5 
V. cholerae O1 Classical 569B TNTCa 44.8 3.4 
(ATCC 25870) 
 
Assay 5 
V. cholerae O1 El Tor (ATCC 39050) 3.7 x 109 cfu/ml 0.7 1.0 
V. cholerae O1 El Tor (CDC) 7.4 x 108 cfu/ml 1.7 2.0 
V. cholerae O1 Classical 569B 4.7 x 109 cfu/ml 55.3 3.0 
(ATCC 25870) 
  
aToo numerous too count.    
    
  
 Alternate induction media.  Vibrio cholerae O1 classical 569B was induced for 
CT production using a petri dish and a beaker with a similar surface area to volume ratio 
of a 10 gallon tank.  For subsequent assays, oysters were harvested from Tampa Bay and 
placed in a 10 gallon tank.  The medium in the tank needed to serve three essential 
functions: 1) maintain the oysters viability 2) allow V. cholerae growth and 3) stimulate 
CT production.  Four types of media were tested in petri dish and beaker trials: salt water 
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culture medium made in DI water (SWC-DI), salt water culture medium made in Instant 
Ocean (SWC-IO), CAYE made in Instant Ocean (CAYE-IO) and CAYE in DI water 
(CAYE-DI) as the control (Figure 24).  The induction protocol previously described was 
used to induce CT production.  
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FIGURE 24.  Toxin induction during V. cholerae growth in four types of media.  A petri 
dish (■) and a beaker (∴) with the same surface to volume ratio of a 10 gallon tank were 
used for these assays.  SWC in DI, salt water culture medium in deionized water; SWC in 
IO, salt water culture medium in instant ocean; CAYE in DI, casamino acids yeast extract 
in deionized water; CAYE in IO, casamino acids yeast extract in instant ocean. 
 
 All four types of media supported CT production in a petri dish.  As seen in Table 
11, three of the four petri dish assays produced cell counts that correlated with those in 
Table 10.  The petri dish culture with the highest cfu/ml (SWC-DI) generated the highest 
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signal to noise ratio while the culture that had the lowest cfu/ml (SWC-IO) generated the 
lowest signal to noise ratio.   
 When running the beaker assays, two types of media allowed for toxin 
production:  SWC-DI and CAYE-IO.  The SWC-IO tank simulation failed to support the 
growth of any V. cholerae (Table 11).  Cell counts for the beaker assays (tank simulation) 
never reached those of the petri dishes.   
 
TABLE 11.  Viable cell counts for CT induction utilizing alternative media. 
  Culture conditions Cell count 
 
 Petri dish – SWC-DI 4.0 × 109 cfu/ml 
 Petri dish – SWC-IO 1.1 × 107 cfu/ml 
 Petri dish – CAYE-DI (control) 3.6 × 109 cfu/ml  
 Petri dish – CAYE-IO 3.1 × 109 cfu/ml 
 Beaker assays – SWC-DI 9.0 × 107 cfu/ml 
 Beaker assays– SWC-IO 0 cfu/ml 
 Beaker assays - CAYE-DI (control) 3.8 × 107 cfu/ml 
 Beaker assays – CAYE-IO 3.5 × 108 cfu/ml 
    
  
 
Toxin Spiked Oysters  
 The detection of CT in an oyster matrix was tested using the Analyte 2000.  Store 
purchased oysters were processed according to Tamplin and Capers (168).  Oysters were 
spiked with 10 ng/ml of CT and waveguides were prepared with 1.5 µg/ml of GM1 as 
previously described.  The assay was done in a progressive manner: buffer was assayed, 
followed by assays for an oyster, a spiked oyster and then the CT standard.  The limit of 
detection was determined for each Analyte 2000 channel.  All four of the channels 
generated false positives with the unspiked oyster matrix (Table 12).  All of the channels 
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were positive for the spiked oyster matrix and the standard.  Based on the false positives 
obtained for the unspiked oyster matrix, it was hypothesized that there were proteins 
present that were cross reacting with the detection antibody.   
 
TABLE 12.  Toxin spiked oyster homogenate samples analyzed with the Analyte 2000.  
This is a representative sample of waveguides tested.   
 
          Channel a 
 
 1  2  3  4  
  
 
LOD 13 12 23 38 
 
Change in signal (pA) for 
Buffer -3 -4 -6 -10 
Oyster 40.0 87 111 153 
Spiked oyster 383 386 625 375 
100 ng/ml CT 1781 1306 2260 1377 
 
 
anumbers in bold are positive signals. 
 
Cross-Reactive Proteins 
 Affinity for polyclonal anti-CT-B rabbit antibody. A Western blot was performed 
to determine if the Analyte 2000 values shown in Table 12 for the unspiked oyster 
homogenate were false positives.  Four different oysters were processed and analyzed for 
cross-reactive proteins. Electrophoresed proteins transferred onto nitrocellulose filter 
were probed with polyclonal anti-CT-B antibody (Figure 25).  Two protein bands reacted 
with the anti-CT-B (Figure 25).  One band had a molecular weight of approximately 100 
kD and one had a molecular weight of approximately 60 kD.  The CT holotoxin has a 
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molecular weight of 85 kD, the A subunit has a molecular weight of 27.2 kD and the B 
subunit has a molecular weight of 11.6 kD.  CT and CT-B molecular weights do not 
correspond with 100 and 60 kD; therefore, the presence of these proteins suggests that the 
false positives may be due to cross-reactive proteins 
  
                  
    
                                                                                                     
 
      
FIGURE 25.  Western blot of four unspiked oyster samples.  Lane 1, marker; Lane 2, 
buffer; Lane 3, 75 ng CT- β; Lane 4, unspiked oyster A; Lane 5, unspiked oyster B; Lane 
6, unspiked oyster C; Lane 7, unspiked oyster D; Lane 8, 75 ng CT- β. 
        
    
 
 Affinity for IgG antibody. The Western Blot was repeated in order to determine if 
the two cross reactive proteins (100 kD and 60 kD) seen in Figure 25 were binding 
specifically to the polyclonal anti-CT-B rabbit antibody (Biogenesis) or just binding 
nonspecifically to IgG antibody (Figure 26).  Incubation with a primary antibody was 
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eliminated and the membrane was incubated directly with anti-rabbit IgG conjugated to 
alkaline phosphatase.  The only visible bands were those of the molecular weight marker, 
indicating the 100 kD and 60 kD cross-reactive proteins were binding specifically to the 
anti-CT-B antibody. 
 
         
 
FIGURE 26. Western blot of oyster homogenate utilizing goat anti-rabbit IgG conjugated 
to alkaline phosphatase only.  Lane 1, marker; Lane 2, 75 ng CT; Lane 3, buffer; Lane 4, 
oyster homogenate spiked with 10 ng/ml CT; Lane 5, buffer; Lane 6, oyster homogenate; 
Lane 7, buffer; Lane 8, buffer; Lane 9, 75 ng CT; Lane 10, buffer. 
 
 Specificity for GM1.  ELISAs were performed to determine if the oyster matrix 
was binding to GM1.  Two types of samples were tested: (1) APW spiked with 100 ng/ml 
of CT and (2) unspiked oyster homogenate. Samples were fractionated by size using a 
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P10 column and fractions were collected in 500 µl volumes. Samples were directly 
adsorbed to wells (Figure 27) or captured using 1.5 µg/ml of GM1 per well (Figure 28).  
All of the fractions from both samples were tested.  
 Figures 27 and 28 illustrate that the oyster homogenate did not exhibit nonspecific 
binding to the wells of the 96-well microtitre plate.  The fractionated oyster homogenate 
displayed no specificity or binding activity with the ganglioside GM1.  All 10 fractions 
had a signal to noise ratio of less than 2 and, therefore, were considered negative.  ELISA 
results would also indicate the level of nonspecific binding of the oyster matrix to the 
plate and to GM1.  It was concluded based on Figures 27 and 28 that the cross-reactive 
proteins bind to anti-CT-B antibody and do not bind to GM1. 
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FIGURE 27.  ELISA values for fractions of oyster sample adsorbed directly to ELISA 
wells.  Ten fractions from oyster homogenate (♦) and APW spiked with 100 ng/ml CT (▪) 
were tested for binding to GM1. 
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FIGURE 28. ELISA values for GM1 based assay.  Ten fractions from oyster homogenate 
(♦) and APW spiked with 100 ng/ml CT (▪) were tested for binding to GM1.  
 
 Removal of cross-reactive proteins from oyster matrix.  The cross-reactive 
proteins in the oyster were removed by passage through a P10 gel bed.  Five hundred 
microliters of oyster homogenate spiked with 5 µg/ml of CT and unspiked oyster 
homogenate were passed through two separate P10 columns with a 10 ml bed volume.  
The columns were equilibrated with PBS with 0.1% sodium azide.  Ten 500 µl fractions 
were collected and analyzed using an ELISA (Figure 29) and the Analyte 2000 (Table 
13).  Fractions 6 through 10 contained the cholera toxin from the spiked sample.  None of 
the fractions from the unspiked sample contained cholera toxin or other proteins that 
would generate a positive ELISA signal.  According to ELISA results, fractions 7 and 8 
should have high concentrations of CT.  Fractions 7 and 8, were analyzed using the 
Analyte 2000 (Table 13).  Positive signals were generated when fractions 7 and 8 of the 
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spiked sample were assayed. Negative signals were obtained for the nonspiked fractions 
7 and 8.  Fractionating the oyster matrix through the gel column may have removed the 
cross-reactive proteins or diluted them to undetectable concentrations.  
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FIGURE 29. ELISA values for oyster homogenate fractions.  Oyster homogenate spiked 
with 5 µg/ml of CT (♦) and unspiked oyster homogenate (▪) were fractionated.  All ten 
fractions from each sample were tested.  
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TABLE 13. Analyte 2000 values for oyster homogenate fractions. 
 
      Channela 
 
 1 2 3 4 
 
                                                          Fraction 7            Fraction 8           Fraction 7            Fraction 8 
                                                       spiked                     spiked                unspiked             unspiked 
   
 
LOD 0 4 7 36 
 
Change in signal for 
APW -1 0 -2 -1 
Sample 899 645 0 -1 
anumbers in bold are positive signals. 
 
Tank Inoculation 
 Instant Ocean as induction medium. A 10 gallon aquarium was filled with 10 L of 
Instant Ocean.  The temperature of the tank was maintained at 30 °C.  This is the 
optimum temperature to induce CT production.  Oysters were harvested from Tampa Bay 
during low tide.  The oysters were scrubbed to remove loose particles and placed in the 
aquarium.  Oyster shells remained closed confirming viability.  After 24 hours,  
V. cholerae O1 569B ATCC 25870, was inoculated into the tank at a final concentration 
of 7.27 × 104 cfu/ml.  Organisms were enumerated with alkaline peptone broth by the 
five tube MPN enrichment method.  After 6 hours of incubation in a 42°C waterbath, all 
turbid tubes were streaked on TCBS agar for the isolation of V. cholerae (41, 111).   
V. cholerae was identified using PCR and API 20E.  V. cholerae and other bacteria were 
recovered from the oyster and Instant Ocean at 6 and 12 hours and presumptively 
identified by API 20E (Table 14).  Table 15 lists the cfu/g (oyster matrix) or cfu/ml (tank 
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medium) determined by a 5 tube MPN.  V. cholerae was no longer recovered from the 
oyster or Instant Ocean after 12 hours of incubation.  Cell counts listed in Table 15 were 
at least 1000-times lower than those observed using the petri plate toxin induction 
method.  The lower cell counts suggested that V. cholerae cells would not produce toxin.  
The ELISA values (Figure 30) confirmed the lack of CT production.   
 
TABLE 14.  Isolates presumptively identified by API 20E for Instant Ocean tank. tc, 
control oysters processed at time of harvest; t0, samples placed in tank, processed 24 
hours after harvest and immediately prior to tank inoculation; t6, t12, t24, t48, and t72,  
samples processed 6, 12, 24, 48, and 72 hours after tank inoculation respectively; oyster 
or Instant Ocean, type of sample.   
 
 Time point and sample at collection  Isolate identification 
Control oyster - tc   Aeromonas hydrophila, Klebsiella ozaenae,  
  Vibrio parahaemolyticus 
Oyster – t0  Klebsiella ozaenae 
Instant Ocean – t0  Vibrio parahaemolyticus 
Oyster – t6  Escherichia coli, Vibrio cholerae 
Instant Ocean – t6  Vibrio parahaemolyticus, Vibrio fluvialis,  
  Vibrio cholerae 
Oyster – t12  Vibrio parahaemolyticus, Vibrio cholerae 
Instant Ocean – t12 Vibrio fluvialis, Vibrio cholerae 
Oyster – t24  Vibrio fluvialis 
Instant Ocean – t24 Vibrio fluvialis 
Oyster – t48  Aeromonas hydrophila 
Instant Ocean – t48 Vibrio fluvialis 
Oyster – t72  unidentifiable 
Instant Ocean – t72  Escherichia coli 
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TABLE 15. Cell counts for Vibrio cholerae recovered from oyster and Instant Ocean.  t6, 
and t12, samples processed 6 and 12 hours after tank inoculation; oyster or Instant Ocean, 
type of sample.   
 
Time point and sample at collection     Cell count 
 
 Oyster – t6  4.0 × 104 cfu/g 
 Instant Ocean – t6  2.5 × 104 cfu/ml 
 Oyster – t12  6.5 × 103 cfu/g 
 Instant Ocean – t12  6.5 × 104 cfu/ml 
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FIGURE 30.  ELISA values for samples from tank inoculation with Instant Ocean. 
Oyster homogenate was fractionated as described previously and assayed for the presence 
of CT.  Control oysters (♦), oysters at t0 (▪), oysters at t6 (▲) and oysters at t12 (■) were 
all negative for CT. 
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 Isolates presumptively identified by API 20E as V.  cholerae were confirmed by 
PCR using two sets of primers and predicted lengths:  its (Figure 31) and ctxA (Figure 
32).  The its primers were designed to amplify the 16S-23S rRNA intergeneic spacer 
region of V. cholerae (21).  The ctxA primers were designed to amplify the genes 
encoding the A subunit of CT (48).  Figure 31 shows positive amplification of its gene 
from V. cholerae isolates at 6 and 12 hour time points.  Figure 32 shows positive 
amplification of ctxA gene from V. cholerae isolates at both time points. 
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FIGURE 31. PCR of isolates using its primers. Lane1, ladder; Lane 2, positive control  
V. cholerae; Lane 3, negative control E. coli; Lane 4, presumptive V. cholerae from 
oyster at t6; Lane 5, presumptive V. cholerae from Instant Ocean at t6; Lane 6, 
presumptive V. cholerae from oyster at t12; Lane 7, Presumptive Vibrio cholerae from 
Instant Ocean at t12. 
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FIGURE 32.  PCR of isolates using ctxA primers. Lane 1, ladder; Lane 2, positive control 
V. cholerae; Lane 3, negative control E. coli; lane 4, presumptive V. cholerae from oyster 
at t6; Lane 5, presumptive V. cholerae from Instant Ocean at t6; Lane 6, presumptive V. 
cholerae from oyster at t12; Lane 7, presumptive V. cholerae from Instant Ocean at t12;  
            . 
   
 SWC-DI as induction medium.  SWC-DI simulates the previously described petri 
dish protocol.  A 10 gallon aquarium was filled with 10 L of SWC-DI.  The temperature 
of the tank was maintained at 30°C.  Oysters harvested from Tampa Bay were placed in 
the aquarium for 24 hours.  Vibrio cholerae O1 569B ATCC 25870 was then inoculated 
into the tank at a final concentration of 4.56 × 104 cfu/ml.  After 0, 6, 12, 24, and 48 hour 
time points organisms were recovered from the oyster matrix and the tank medium.  
Table 16 lists those isolates presumptively identified by API 20E.  Vibrio cholerae was 
not recovered from the oyster matrix or the SWC medium at any time interval.  The 
inability to recover any V. cholerae leads to the conclusion that it would be highly 
unlikely that CT production would have occurred.  The ELISA testing for the presence of 
        1         2           3        4            5          6          7      
predicted 564 
bp amplicon  
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CT (Figure 33) confirmed the lack of CT production within the oyster matrix or tank 
medium.   
 
TABLE 16. Isolates presumptively identified by API 20E for SWC-DI tank.  Oyster and 
tank medium samples were collected at varying time intervals.  Ten oysters from each 
tank were scrubbed, their meat pooled and homogenized 1:1 in PBS followed by serial 
dilution in PBS (111).  A five tube MPN was prepared by enriching dilutions of oyster 
homogenate or tank medium in APW (pH 8.5) at 42°C for 6 hours in a water bath.  Each 
tube in the MPN series was then streaked onto TCBS (41).  Plates were incubated at 37° 
C for 18 hours.  Individual colonies were resuspended in PBS for presumptive 
identification by API 20E.  tc, control oysters processed at time of harvest; t0, samples 
placed in tank, processed 24 hours after harvest and immediately prior to tank 
inoculation; t6, t12, t24, and t48,  samples processed 6, 12, 24, and 48 hours after tank 
inoculation, respectively; oyster or Instant Ocean, type of sample.   
 
 Time point and sample at collection Isolate identification 
  
 Control oyster - tc  Vibrio parahaemolyticus 
 Oyster – t0   Vibrio parahaemolyticus 
 SWC-DI – t0   Vibrio parahaemolyticus 
 Oyster – t6   Vibrio alginolyticus 
 SWC-DI – t6   unidentifiable 
 Oyster – t12   Vibrio parahaemolyticus 
 SWC-DI – t12   Escherichia coli 
 Oyster – t24   Vibrio alginolyticus 
 SWC-DI – t24   Vibrio alginolyticus 
 Oyster – t48   No growth 
 SWC-DI – t48   Vibrio alginolyticus 
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FIGURE 33. ELISA for the detection of CT after V. cholerae inoculation of tank 
containing SWC-DI.  Oyster samples (■) and SWC-DI (∴) were assayed at different time 
intervals for the presence of CT.  The ganglioside GM1 was used as the capture molecule 
and the primary antibody was the anti-CT antibody.  A signal to noise ratio greater than 2 
was a positive value. 
  
 CAYE-IO as induction medium.  CAYE-IO simulates the previously described 
petri dish protocol.  A 10 gallon aquarium was filled with 10 L of CAYE-IO and was 
inoculated with V. cholerae.  The temperature of the tank was maintained at 30°C.  At 24 
hours post inoculation, ten mls of the liquid was transferred to a new tank containing 
CAYE-IO with 0.2% glucose.  The in vitro induction assays described previously utilized 
fresh CAYE medium with 0.2% glucose for CT induction at 24 hours post inoculation.  
Oysters were harvested from Tampa Bay and then added to the aquarium.  After 24 
hours, V. cholerae O1 569B ATCC 25870, was inoculated into the tank at a final 
concentration of 4.56 × 104 cfu/ml.  At 0, 6, 12, 24, and 48 hour time points organisms 
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were recovered from the oyster matrix and the tank medium.  Table 17 lists those isolates 
presumptively identified by API 20E.  Vibrio cholerae was not recovered from the oyster 
or SWC at any time interval.  It was unlikely that CT was produced without the growth of 
any viable V. cholerae.  ELISA detecting the presence of CT (Figure 34) confirmed the 
absence of CT production.   
 
TABLE 17. Isolates presumptively identified by API 20E recovered from CAYE-IO with 
0.2% glucose tank.  tc, control oysters processed at time of harvest; t0, samples placed in 
tank, processed 24 hours after harvest and immediately prior to tank inoculation; t6, t12, 
t24, and t48, samples processed 6, 12, 24, and 48 hours after tank inoculation, respectively; 
oyster or Instant Ocean, type of sample.   
 
 Time point and sample at collection Isolate identification 
 
 Control oyster - tc  Vibrio parahaemolyticus 
 Oyster – t0   Vibrio parahaemolyticus 
 CAYE – t0   Vibrio parahaemolyticus 
 Oyster – t6   Vibrio alginolyticus, Vibrio  
    parahaemolyticus 
 CAYE – t6   Vibrio alginolyticus, Vibrio   
    parahaemolyticus 
 Oyster – t12   Vibrio alginolyticus 
 CAYE – t12   Vibrio alginolyticus 
 Oyster – t24   Vibrio alginolyticus 
 CAYE – t24   Vibrio alginolyticus 
 Oyster – t48  No growth 
 CAYE with 0.2% glucose – t48 Vibrio alginolyticus 
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FIGURE 34.  ELISA detecting presence of CT from tank containing CAYE-IO with 
0.2% glucose, inoculated with V. cholerae.  Oyster samples (■) and CAYE-IO with 0.2% 
glucose (∴) were assayed at different time intervals for the presence of CT.  All samples 
assayed were negative for CT. 
 
Biosensor Immunoassay Development for the Detection of Botulinum Toxin 
BCA Protein Assay 
 No concentrations were provided with the botulinum toxoids received from the 
CDC.  Only dilution factors were given:  type A @ 1:10,000 and type B @ 1:1,000.  A 
BCA protein assay was performed to determine the actual protein concentration of each 
toxoid.  The correlation coefficient (r) of the line was 0.997. The extrapolated values are 
listed in Table 18 but their validity is questionable.  The absorbance readings for each of 
the toxoids were below the reading of the lowest known BCA concentration and, 
therefore, determined to be invalid.  Thus, it was determined that the dilutions to be tested 
would be based on the CDC stock suspension. 
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TABLE 18. Extrapolated botulinum toxoid protein concentrations. 
 
 
 Protein concentration Absorbance @ 562 nm Extrapolated concentration  
  
 0 mg/ml BSA 0 - 
 0.1 mg/ml BSA 0.039 - 
 0.2 mg/ml BSA 0.079 - 
 0.4 mg/ml BSA 0.137 - 
 0.6 mg/ml BSA 0.181 - 
 0.8 mg/ml BSA 0.240 - 
 1 mg/ml BSA 0.296 - 
 Toxoid A 0.019 0.018 mg/ml 
 Toxoid B 0.016 0.028 mg/ml  
 
 
ELISA for Detection of Botulinum Toxoids Using Anti-Botulinum Antibody 
 Anti-botulinum toxoid antibodies obtained commercially and from the CDC 
(Figure 35) were tested for their ability to bind to botulinum toxoids A and B using an 
ELISA.  Serial dilutions of botulinum toxoids A and B were directly adsorbed to the 
wells of a 96-well microtitre plate.  Antibodies to toxoid type A and type B were used as 
primary antibodies at a concentration of 10 µg/ml.  Secondary antibody, anti-rabbit IgG 
conjugated to HRP or anti-goat IgG conjugated to HRP was used at a dilution of 1:500.  
The polyclonal anti-A botulinum toxin antibody produced in goat and the polyclonal anti-
B antibody produced in rabbit, both received from the CDC, bound to their respective 
toxoids (Figure 35).  The CDC anti-toxin A antibody bound toxoid A and could be 
detected at dilutions of 1:100,000 and 1:1,000,000, whereas the CDC ant-toxin B 
antibody bound to toxoid B and could be detected when the toxoid was diluted 1:10,000.  
The Accurate Chemical and Scientific Corporation antibody binding to toxoids A and B 
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could not be detected.  The CDC polyclonal anti-B goat antibody binding to toxoid B 
could not be detected. 
 
0
1
2
3
4
5
1 2 3 4 5 6 7
Dilution 10-x
Si
gn
al
 to
 n
oi
se
 ra
tio
  
 
FIGURE 35.  Detection of botulinum toxoids adsorbed to plate using anti-botulinum 
toxin antibodies.  Antibody affinity for toxoid A and B was tested using an ELISA.  
Botulinum toxoid A and B were detected using antibodies provided by the CDC or 
purchased from Accurate Chemical and Scientific Corporation.  Initial concentration of 
toxoid A was 1:10,000 and type B was 1:1,000.  Combinations of Toxoid A with the 
CDC goat anti-A antibody (♦), Toxoid A with the Accurate antibody (▪), Toxoid B with 
the CDC goat anti-B antibody (▲), Toxoid B with the CDC rabbit anti-B antibody (■) 
and Toxoid B with the Accurate antibody (▬) were all assayed using an ELISA. 
 
Detection of Botulinum Toxoids Using Sandwich ELISA with GT1b Capture 
 A sandwich ELISA was performed with the ganglioside, GT1b in PBS (1.5 
µg/ml) (Figure 36), as a capture molecule.  GT1b was directly adsorbed to the wells of a 
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mirotitre plate.  Serial dilutions of toxoid A and B were captured by the GT1b.  
Commercial or CDC antibodies to toxoid type A and type B were used as primary 
antibodies to detect either toxoids.  Secondary antibody diluted 1:500 was either anti-
rabbit IgG or anti-goat IgG–HRP conjugated.  The signal to noise ratio never reached a 
value of 2.  The ganglioside GT1b showed no specificity for either botulinum toxoids.   
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FIGURE 36. Detection of toxoids A and B using sandwich ELISA with GT1b capture.  
GT1b (1.5 µg/ml) affinity for toxoid A and B was tested using an ELISA.  Botulinum 
toxoid A and B were detected using antibodies provided by the CDC or purchased from 
Accurate Chemical and Scientific Corporation.  Initial concentration of toxoid A was 
1:10,000 and type B was 1:1,000.  Combinations of Toxoid A with the CDC goat anti-A 
antibody (■), Toxoid A with the Accurate antibody (∗), Toxoid B with the CDC goat 
anti-B antibody (▪), Toxoid B with the CDC rabbit anti-B antibody (▲) and Toxoid B 
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with the Accurate antibody (♦) were all assayed using an ELISA.  All five combinations 
produced results that overlapped when graphed. 
   
GT1b-and GD1b-Based ELISA 
 Two of the natural cellular receptors for botulinum toxins are the gangliosides 
GT1b and GD1b.  These receptors were used as capture molecules in the development of 
an ELISA.  Since no positive signal was obtained when the GT1b was used as a capture 
molecule, another ganglioside, GD1b was tested as a capture molecule.  An ELISA was 
performed to determine if there was any specificity between the ganglioside GD1b for 
botulinum toxoid A and/or B (Figure 37).  GD1b was dissolved in PBS at a concentration 
of 1.5 µg/ml.  The primary antibodies used were the CDC goat anti-A and CDC rabbit 
anti-B at a concentration of 10 µg/ml.  The secondary antibody was diluted 1:500 and 
was either anti-rabbit IgG or anti-goat IgG–HRP conjugated.  Neither toxoid could be 
detected using the GD1b capture/antibody detection ELISA format.  Signal to noise ratios 
were below 2 for botulinum toxoid A at 1:100,000 dilution and toxoid B at a 1:10,000 
dilution.  GD1b had no affinity for either botulinal toxoid A or B (Figure 37).   
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FIGURE 37.  Detection of botulinum toxoids A or B using GD1b capture in ELISA.  
GD1b (1.5 µg/ml) affinity for toxoid A and B was tested using an ELISA.  Botulinum 
toxoid A and B were diluted 1:10 and detected using antibodies provided by the CDC.  
Initial concentration of toxoid A was 1:10,000 and type B was 1:1,000.   
  Biosensor Assay Detecting Toxoid Type A Using Liposomes   
 Singh et al. (156) demonstrated that the incorporation of the ganglioside into a 
liposome may allow successful detection of botulinum toxin (156).  Liposomes 
containing Alexafluor 647 were synthesized following the specifications of Singh et al. 
(156) for use as a detection molecule in conjunction with the Analyte 2000.  Due to the 
fluorophore that was incorporated into the liposome being out of the spectral range of the 
fluorometer, the normal progression in the development of a biosensor assay could not be 
followed.  The assay development was initiated with the Analyte 2000.  Toxoid A (1:10 
or 1:100) was adsorbed directly to the waveguide and allowed to incubate for 18 hours at 
4°C.  The waveguides were rinsed with PBS and then incubated in blocking buffer (PBS, 
2 mg/ml casein, 2 mg/ml BSA) and allowed to incubate 18 hours at 4°C.  The 
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waveguides were then rinsed with PBS and liposomes at a dilution of 1:1,000 were 
incubated on the waveguides for 10 minutes.  Table 19 shows representative results from 
a single waveguide assay.  There was a significant increase in pA signal after incubation 
with the liposome followed by PBS rinses for all five channels including the negative 
control (Table 19), 
 
TABLE 19. Biosensor values for toxoid A adsorbed directly to the waveguide.  
Waveguides were incubated with toxoid A for 18 hours, followed by blocking buffer for 
18 hours and then incubated with liposome at a 1:1,000 dilution.  Fluorescent readings 
were recorded for each step of the assay.  Numbers in parentheses indicate incubation 
times. 
  
                                            Channel  
  
 1 2 3 4              Negative 
     control 
   
Toxoid concentration 1:100  1:100 1:10 1:10 PBS 
  
Initial waveguide  
fluorescence 891 1093 1196 1277 670 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min) 1393 2930 20431 6945 1168 
Two × 1 ml PBS wash 5271 7563 22578 6522 2981 
0.2 ml PBST (5 min) 8440 15395 22577 17349 4254 
Two × 1 ml PBS wash 
(final reading) 4975 834 5763 4618 1284 
 
 
 Singh et al. (156) reported that incubation with a detergent (such as PBST or 
Triton X) after addition of liposome disrupts the liposomes and alleviates dequenching of 
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the fluorophore, maximizing fluorescent readings.  Following incubation with PBST for 5 
min, signals increased dramatically with the exception of channel 3, which had reached 
the upper limitations of the machine’s pA signal readout capabilities.  After incubation 
with PBST, two 1 ml rinses with PBS removed any unbound liposomes causing the pA 
signal to decrease.  However, for channels 1, 3, 4, and 5, the pA signal after the final PBS 
rinse was still higher than that prior to liposome incubation.  There was a three-to-five-
fold increase in the final fluorescence compared with the initial reading.  The negative 
control illustrates a substantial amount of liposomes non-specifically sticking to the 
waveguide.  The final reading obtained for the negative control waveguide was double 
the initial fluorescence reading.  A direct sandwich assay format utilizing antibody for 
capture and the liposomes as a detection molecule was attempted.  
Biosensor Assay Utilizing Antibody as a Capture Molecule   
 Varying liposome concentrations as detection molecule for the detection of 
botulinal toxoid type A.  Multiple sandwich biosensor assays were performed utilizing 
different concentrations of liposome as the detection molecule.  Following 18 hours 
incubation with streptavidin, biotinylated goat anti-A antibody (100 µg/ml) was 
incubated for 18 hours at 4°C.  On the following day, the waveguides were rinsed with 
PBS and then incubated for 18 hours at 4°C in blocking buffer.  On the final day, the 
waveguides were rinsed with PBS and an assay was completed with the liposome as the 
detection molecule.  Initially liposomes at 1:1,000 to 1:5,000 dilutions were used as the 
detection reagent (Table 20 and 21).  Biosensor assays using these dilutions of liposome 
produced very high LODs ranging from 117 to 3162.  Table 22 shows results from 
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biosensor assay for the detection of toxoid A using liposomes diluted 1:10,000 and 
1:20,000 for the detection reagent. 
 
TABLE 20.  Sandwich biosensor assay using anti-toxoid A antibody for capture and 
liposomes at 1:1,000 as the detection reagent for the detection of botulinal toxoid type A.  
Fluorescent readings were recorded for each step of the assay.  Numbers in parentheses 
indicate incubation times.  The limit of detection remained high and the botulinum toxoid 
type A was never utilized in the assay. 
         Channela 
 
 1 2 3 4   
Liposome concentration 1:1000 1:1000 1:1000 1:1000 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 5995 2656 6104 3032 
0.2 ml PBST (5 min) 7449 7913 11139 3869 
2 × 1 ml PBS wash 6036 4172 2075 2265 
 
0.2 ml liposome (5 min)  
2× 1 ml PBS wash 6782 3549 5937 3175 
0.2 ml PBST (5 min) 6941 4909 10143 3880 
2 × 1 ml PBS wash 5880 2984 3965 2874 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 5622 1856 2876 3202 
0.2 ml PBST (5 min) 5844 3259 3984 3411 
2 × 1 ml PBS wash 5371 1775 2009 1776 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 5870 1519 2098 2142 
0.2 ml PBST (5 min) 6130 1871 3021 2580 
2 × 1 ml PBS wash 5465 1224 1462 1582 
 
LOD 624 2958 3162 1502 
a numbers in italics are limits of detection. 
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TABLE 21.  Sandwich biosensor assay using anti-toxoid A antibody for capture and 
liposomes at 1:2,500 and 1:5,000 as the detection reagent for the detection of botulinal 
toxoid type A.  Fluorescent readings were recorded for each step of the assay.  Numbers 
in parentheses indicate incubation times.  The limit of detection remained high and the 
botulinum toxoid type A was never utilized in the assay. 
  
        Channela 
  
 1 2 3 4   
Liposome concentration 1:2500 1:2500 1:5000 1:5000 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 1529 1976 2013 1356 
0.2 ml PBST (5 min) 2206 3102 2650 1715 
2 × 1 ml PBS wash 953 1485 1790 1426 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 881 1843 1671 1137 
0.2 ml PBST (5 min) 1359 2335 1970 1311  
2 × 1 ml PBS wash 934 1429 1632 1207 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 1008 1491 1488 1111 
0.2 ml PBST (5 min) 1197 1635 1674 1173 
2 × 1 ml PBS wash 903 1257 1372 1120 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 848 1106 1254 1015 
0.2 ml PBST (5 min) 949 1236 1344 1071 
2 × 1 ml PBS wash 832 1037 1196 973 
 
LOD 117 455 596 417 
 
a numbers in italics are limits of detection. 
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The LODs (Table 20 and 21) were too high to continue with either assay.  Although the 
assay for cholera toxin utilized the ganglioside as a capture molecule, the LOD obtained 
never exceeded values of 40.  When a capture antibody was utilized in the botulinum 
assay, a trend in signals across all four channels was observed:  the fluorescence 
continued to decrease with the addition of liposome followed by subsequent washes.  A 
great deal of variability remained in the background signals and a low LOD was never 
attained.  
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TABLE 22. Sandwich biosensor assay using anti-toxoid A antibody for capture and 
liposomes at 1:10,000 and 1:20,000 as the detection reagent for the detection of botulinal 
toxoid type A.  Fluorescent readings were recorded for each step of the assay.  Numbers 
in parentheses indicate incubation times.  The limit of detection remained high and the 
botulinum toxoid type A was never utilized in the assay. 
  
        Channela 
 
 1 2 3 4   
Liposome concentration 1:10000 1:10000 1:20000 1:20000 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 828 858 933 964 
0.2 ml PBST (5 min) 807 933 951 957 
2 × 1 ml PBS wash 770 721 871 884 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 846 804 929 937 
0.2 ml PBST (5 min) 885 844 949 937 
2 × 1 ml PBS wash 789 695 850 872 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 798 766 926 895 
0.2 ml PBST (5 min) 805 790 926 903 
2 × 1 ml PBS wash 750 691 852 863 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 815 693 864 890 
0.2 ml PBST (5 min) 845 693 883 887 
2 × 1 ml PBS wash 839 683 861 868 
 
LOD 133 150 79 53 
anumbers in italics are limits of detection. 
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 A 1:10,000 or 1:20,000 dilution of liposome may have eliminated the nonspecific 
binding or it is possible that a smaller concentration of liposome eliminated the signal 
completely.   
 An assay was performed with toxoid type A diluted 1:10 in PBS-BSA 0.1% 
(Table 23).  One hundred ug/ml of goat anti-A antibody was used as the capture 
molecule.  Varying liposome concentrations were utilized for the detection of the protein. 
 
 
TABLE 23. Sandwich biosensor assay with varying liposome concentrations for the 
detection of botulinal toxoid type A.  Fluorescent readings were recorded for each step of 
the assay.  Numbers in parentheses indicate incubation times.  Buffer was assayed 
followed by botulinum toxoid type A. 
 
        Channela 
  
 1 2 3 4   
liposome 1:1000 1:1250 1:2500 1:5000 
 
LOD 64 196 73 74 
Signal (pA) after 5 minute 
incubation with liposome 
 
PBS-BSA 0.1%  30 46 -77 -50 
 
1:10 Type A Toxoid  33 -110 -11 -18 
anumbers in italics are limits of detection. 
 
 Changes in signal values higher than the calculated LOD were treated as positive 
values.  All of the buffer samples generated negative signals (Table 23).  Unfortunately, 
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subsequent incubation with the toxoid yielded negative signals as well.  The assay for 
botulinum toxin with the Analyte 2000 produced LODs that were too high for valid 
results or negative signals for the protein of interest.  The inherent nature of the liposome 
to bind nonspecifically to the surface of the polystyrene waveguide made it an 
impractical detection molecule for the botulinum A toxin. 
 Varying liposome concentrations as detection molecule for the detection of 
botulinal toxoid type B.  Toxoid type A had a higher degree of probability of generating 
positive signals compared to type B toxoid in the Analyte 2000 assay.  All of the initial 
assays were performed using toxoid type A and the CDC goat anti-A antibody.  The 
results indicate that the utilization of the liposomes as the detection molecule in 
conjunction with the Analyte 2000 was not successful (Table 20, 21, and 22).  The 
synthesized liposomes were developed for the intended detection of toxoid type B and 
type A, since both botulinal toxoids utilize the same receptor, GT1b.  Considering the 
results for toxoid type A, it would be improbable that the detection of toxoid type B 
would be successful.  Bearing this in mind, biosensor assays for the detection of toxoid 
type B (Tables 24 and 25) were attempted utilizing concentrations of liposome at lower 
and higher concentrations of liposome dilution.  The same procedure was followed as that 
used for toxoid type A with a different capture antibody (biotinylated CDC rabbit anti-B 
antibody). 
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TABLE 24.  Biosensor assay with liposome concentration at 1:1,000 for the detection of 
botulinal toxoid type B.  Fluorescent readings were recorded for each step of the assay.  
Numbers in parentheses indicate incubation times.  The limit of detection remained high 
and the botulinum toxoid type B was never utilized in the assay. 
 
       Channela 
 
 1 2 3 4   
Liposome concentration 1:1000 1:1000 1:1000 1:1000 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 4261 2975 10755 10724 
0.2 ml PBST (5 min) 6466 4072 11955 11737 
2 × 1 ml PBS wash 2036 1964 7242 8513 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 3875 3364 7915 8768 
0.2 ml PBST (5 min) 4747 4256 8258 9073 
2 × 1 ml PBS wash 1505 1976 6806 8208 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 2369 2355 6988 8331 
0.2 ml PBST (5 min) 3144 2068 7179 8396 
2 × 1 ml PBS wash 998 12466 6027 8248 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 1385 1605 6792 8158 
0.2 ml PBST (5 min) 1509 1458 6858 8153 
2 × 1 ml PBS wash 1004 1087 6635 8076 
 
LOD 3124 1130 1024 123 
anumbers in italics are limits of detection 
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TABLE 25.  Biosensor assay with liposome concentrations of 1:10,000 and 1:20,000 for 
the detection of botulinal toxoid type B.  Fluorescent readings were recorded for each 
step of the assay.  Numbers in parentheses indicate incubation times.  The limit of 
detection remained high and the botulinum toxoid type B was never utilized in the assay. 
 
             Channela 
 1 2 3 4   
Liposome concentration 1:10000 1:10000 1:20000 1:20000 
 
Signal (pA) after assay step 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 1426 1212 3680 1283 
0.2 ml PBST (5 min) 2259 1557 4148 1344 
2 × 1 ml PBS wash 1396 919 2095 946 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 2346 1816 1684 1101 
0.2 ml PBST (5 min) 2903 2017 1888 1268 
2 × 1 ml PBS wash 1255 1171 1205 995 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 1420 990 1100 1043 
0.2 ml PBST (5 min) 1562 1064 1121 1084 
2 × 1 ml PBS wash 937 802 964 904 
 
0.2 ml liposome (5 min)  
2 × 1 ml PBS wash 895 915 958 921 
0.2 ml PBST (5 min) 903 940 975 955 
2 × 1 ml PBS wash 665 707 896 887 
 
LOD 741 672 1258 164 
anumbers in italics are limits of detection 
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Low limits of detection (<40 based on cholera assays) were never achieved (Table 24 and 
25).  Due to the inability to reduce the background fluorescence when utilizing liposomes 
as the detection molecule, this concluded any further attempt to detect botulinal toxoid. 
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DISCUSSION 
 The exotoxins of V. cholerae and C. botulinum have different cell specificities 
and modes of action.  Yet, both of these biological toxins can cause serious human 
disease.  V. cholerae has the potential to cause pandemic illness.  C. botulinum produces 
one of the deadliest biological toxins known and can kill within 24 hours. Botulism, and 
cholera, are rarely seen in the United States and the chances of naturally acquiring one of 
these illnesses is low; however, both toxins can be purposefully disseminated and cause 
mass disease.  
 In October of 2001, the world witnessed the response of both public and private 
sector agencies to the intentional release of Bacillus anthracis spores through the mail 
system.  Public health agencies learned with the release of the spores, they would need 
access to rapid and sensitive detection methods for the protection of the public health.  
Conventional laboratory test methods for the identification of potential bioterrorism 
agents may not provide public health care officials with the rapid results needed to 
prevent the dissemination of the potential agent.  Conventional methods typically require 
multiple steps:  enrichment, isolation and serological and/or biochemical tests.  These 
methods are time consuming, resulting in delayed detection and, more importantly, are 
difficult to apply in the field.  The ability to rapidly and accurately detect contaminated 
food and water would serve to reduce the spread of disease.  The goal of this research 
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was development of a rapid and sensitive ganglioside-based assay for the identification of 
cholera and/or botulinum toxins utilizing an evanescent wave biosensor. 
 Conventional serological tests including co-agglutination tests (72, 128), enzyme-
linked immunosorbent assays (ELISA) (104, 151) membrane-based assays (172) and 
PCR (52) may be used for rapid identification of the etiological agent.  The need for 
special equipment and trained employees are not the only inherent weaknesses associated 
with these methods; problems with cross-reactivity can also hinder the assay (104).  The 
polymerase chain reaction (PCR) may also be used to detect bacterial pathogens (52); 
however, special equipment and trained employees are needed as well as clean facilities 
(91).  Also, PCR lacks the capability of detecting a protein product from the cell.  
Therefore, PCR would be inefficient at detecting either protein from V. cholerae or C. 
botulinum.  Enrichment from a complex matrix can be used to obtain the necessary 
number of organisms to perform an ELISA or PCR; however, this may take an additional 
one to two days, thereby negating the test as a rapid method of identification (52, 151).  
These shortcomings coupled with the realization that positive identification of the 
organism when using an ELISA or PCR does not give an indication of the toxicity 
associated with the serotype can make these methods less advantageous than the 
detection of the toxic protein (64, 91). 
 Prompt diagnosis of cholera or botulism is essential to the patient and the health 
care worker.  Botulism is most effectively treated early after the appearance of symptoms 
(13, 148).  Of the more than 193 recognized Vibrio cholerae serotypes, only the O1 and 
O139 serotypes are capable of causing epidemic and pandemic cholera (20).  Rapid 
diagnosis of the serotype or the virulence factor is important due to the virulence of the 
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O1 and O139 serotypes and their potential to cause disease.  Identification of the 
characteristic rice-water stool can allow one to make a presumptive diagnosis; however, a 
definitive diagnosis relies on the isolation of the organism from either feces or vomit, 
followed by serological and/or chemical tests (78, 112).   
 The Analyte 2000 fiber optic-based biosensor assay provides an innovative 
alternative to conventional methods for obtaining near real-time (20-min) results.  Fiber-
optic biosensors have been utilized in the detection of the fraction 1 antigen of Yersinia 
pestis (10), Clostridium botulinum toxin A (118), pseudexin and ricin toxin (71, 119) 
trinitrotoluene (TNT) (90), staphylococcal enterotoxin (169) and bacterial pathogens (37, 
38, 43, 86, 92).  The biosensor can analyze four samples simultaneously and use a variety 
of biomolecules for either capture or detection of the Analyte (92).  One advantage of the 
Analyte 2000 is the ability to produce specific results in a complex matrix (37, 38, 39, 86, 
171).     
 The CDC currently lists Vibrio cholerae as a category B critical agent (142).  A 
study done by Levine et al. with American volunteers showed that different dosages of 
purified oral CT elicited different responses (88).  An oral dose of at least 5 µg was 
required to initiate diarrheal symptoms.  Based on the LD50 in mice, 313 mg of CT/100 lb 
of body weight would be required to cause illness (53).  Rowe-Taitt et al. utilized 
ganglioside-based assays for the detection of cholera toxin in an indirect immunoassay 
using an array biosensor and generated limits of detection of 40 ng/ml and 1 µg/ml 
depending on the species the detection antibody was directed against (143).  The 
sensitivity of the ganglioside-based assay developed in this research was 1 ng/ml.  The 
assay is sensitive and specific but more importantly, repeatable.   
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 The Analyte 2000 uses a polystyrene waveguide as the sample platform.  There 
was always variability with the signals between different waveguides.  In order to 
account for variation among each waveguide due to the manufacturing process, the 
signals from different waveguides were normalized.  Normalization was performed by 
dividing the sample change in signal by the change in signal of the 100 ng/ml CT 
standard and multiplying by 100 (85).  Normalization allowed for the comparison of 
values between individual waveguides throughout the entire study. 
 The biosensor assay relies on detection of the analyte based on the distance of the 
evanescent wave from the surface of the waveguide.  Currently, the evanescent wave is 
propagated approximately 100-1000 nm from the surface of the polystyrene waveguide.  
Typically, the fluorescence of any fluorophore falling within this distance is reverberated 
back into the waveguide and the signal is recorded by a computer in picoAmperes (pA).  
The CT toxin assay developed within this project was consistent and reproducible based 
primarily on the small size of the protein.  Bacteria are large (average E. coli is 1 µm 
wide by 6 µm long).  A typical sandwich immunoassay consists of an antibody bound to 
a solid surface, followed by the binding of the analyte and then the attachment of an 
antibody conjugated to a fluorophore.  When the analyte is a bacterium, it has a higher 
potential for the cell to fall outside of the evanescent wave.  In contrast, a small protein 
like CT typically falls within the evanescent wave, therby produceing repeatable and 
accurate results.  The CT assay developed was successful whether the source of the toxin 
was commercially purchased or produced naturally by the V. cholerae cells.  The ELISA 
and Analyte 2000 were able to detect both sources of CT. 
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 Environmental sources of cholera toxin include contaminated food and water.  
Identification of the organism V. cholerae from contaminated water followed by assaying 
for either cholera toxin or the ctx gene has been reported (96, 108, 175).  Most research 
has focused on assaying for the presence of cells in contaminated food and not the 
cholera toxin (51, 62, 77, 96, 98, 122, 164).  The method developed in this project relies 
on assaying for CT in a complex matrix, an oyster.  Initially, two cross-reactive proteins 
(with molecular weights of approximately 60 and 100 kD) presented problems in 
accurately detect the presence of CT.  However, fractionating the oyster homogenate via 
a P10 column eliminated the cross-reactive proteins.  The Analyte 2000 was able to 
detect the presence of CT at a concentration of 5 µg/ml in artificially-contaminated 
oysters.  The only information known about the two cross-reactive proteins is their 
approximate molecular weight.  It was unexpected to find two proteins within the oyster 
matrix that had an affinity for the anti-CT antibody.  A future research project could 
include sequencing these two proteins as an initial step in identifying them. 
 With the ability to induce toxin production in vitro and detect the protein in the 
oyster tissue using the Analyte 2000, a tank with live oysters was inoculated with a toxin- 
producing strain of V. cholerae.  The aim of the assay was to simulate the ocean 
environment with live oysters, introduce V. cholerae into the system, allow the oysters to 
concentrate the organism via filter feeding and assay for the production of CT within the 
oyster.  The Analyte 2000 assay would be utilized to detect the toxin.  The success of the 
assay was dependent on the ability of the V. cholerae to grow and proliferate within the 
tank and the oysters to remain viable.  Three different types of media were used to 
support the growth and viability of the cells and the oysters:  Instant Ocean, SWC-DI and 
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CAYE-IO.  Instant Ocean is used to maintain a saltwater tank, SWC is used for 
enrichment of marine microorganisms, and CAYE was used in this research study for in 
vitro toxin production. 
 Previous assays developed as part of this project showed that in order for in vitro 
toxin production to occur, V. cholerae required 24 hours for growth and needed to reach a 
concentration of approximately 109 cfu/ml.  The Instant Ocean tank was able to support 
V. cholerae growth for 12 hours and the oysters remained viable for up to 72 hours.  The 
maximum cell count obtained from either the oysters or the medium was approximately 
104 cfu/ml.  Cholera toxin was not detectable in either the oyster or the tank medium.  
These results were not unexpected in as much as the cell count was five logs lower than 
needed and the cells were not detectable past 12 hours of inoculation with V. cholerae.  
The tank with the SWC-DI was less capable of supporting V. cholerae growth and CT 
production than the tank with the Instant Ocean.  Vibrio cholerae was undetectable at any 
time in either the oyster or the tank medium.  The oysters in this tank only remained 
viable for 24 hours while the tank medium itself turned into a viscous form with little to 
no resemblance of the original medium.  CT was not detected in the oysters or the tank 
medium.  The tank with the CAYE-IO has results similar to the SWC-DI tank.  Vibrio 
cholerae and CT were undetectable at any time in either the oyster or the tank medium.  
This tank also turned into a viscous medium and the oysters were dead by 24 hours.  Like 
the SWC-DI tank, CT went undetected as well. 
 While V. cholerae was not detected by culturing in two of the three tanks, cells 
may have been present.  Extensive research has demonstrated that these cells enter the 
VBNC state under stressful conditions (7, 26, 66, 73, 157, 187).  The physical appearance 
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of the tank, the death of the oysters and other small crustaceans, as well as the 
proliferation of other Vibrio spp. and other nonbacterial microorganisms may have placed 
the cells in a stressful environment. It is also important to recognize the impact on an 
isolate when removing it from laboratory growth conditions and placing it into an 
environmental simulation:  specific genes may be turned on, off, rearranged or lost (109).  
It is possible to have the same impact on the genetics of the microorganism when going 
from environmental conditions to laboratory conditions.   
 Vibrio parahaemolyticus and Vibrio alginolyticus were recovered from both tanks 
in instances where V. cholerae was not recoverable; these other bacteria could have out-
competed V. cholerae for available nutrients.  Molecular methods for the ctxAB gene or 
fluorescent microscopy could not be used to determine if the V. cholerae cells were 
present in the tank but possibly entered into the VBNC state because the cells were 
intentionally inoculated into the tank.  Molecular or immunological methods would detect 
the DNA or antigenic determinants of the cells that were present as a result of deliberate 
inoculation. 
 It is also important to consider the realistic application of assaying for the toxin in 
seawater.  The dilution factor the ocean would provide must be taken into consideration.  
The toxin may be secreted into the ocean by toxigenic cells but it would be 
extraordinarily diluted so that it may never be detected by available conventional 
methods.  Seawater samples could be concentrated to recover CT in low concentrations.  
The inability to detect CT was not a function of the Analyte 2000 but a function of the 
tank simulation itself.  There were unknown variables in the tank system that did not 
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allow for the growth of V. cholerae cells.  Without the growth of the cells, there is no CT 
expression. 
 There are many complex interactions required for the growth, proliferation, 
expression of virulence and transmission of V. cholerae in the ocean environment (95).  
Research by Raskin et al. indicated that the in vivo signals that affect the ToxR regulon in 
control of virulence factors in Vibrio cholerae were unknown (131).  The regulon can be 
induced in vitro by different environmental signals such as pH, osmolarity and 
temperature (131).  Taking into account the complex environmental interactions and the 
lack of knowledge of the signals needed to activate the ToxR regulon, the lack of in vivo 
toxin induction in the tank simulation was not totally unexpected. 
 All of the tank simulations were performed without a filtration system.  The 
oysters were harvested directly from Tampa Bay and were contaminated with other 
bacterial and mycotic organisms.  The lack of filtration allowed for the accumulation of 
these microorganisms and waste products in the tank environment.  If a filter had been 
used, then the V. cholerae cells would have been removed from the tank.  However, other 
cells were allowed to grow and proliferate.  The proliferation of these organisms may 
have out-competed the V. cholerae for nutrients, thereby making CT production difficult, 
if not impossible under these conditions.   
 The initial in vitro induction assays were performed in pure culture.  It may be 
advantageous to return to the pure culture petri dish assays in order to determine the 
limiting factors in the tank simulation.  Future assays could test the effect growth of other 
organisms found in the tank simulation have on the toxin-producing capabilities of V. 
cholerae.   
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 One of the first assays attempted with the live oysters was to inoculate a single 
oyster in a large beaker (data not reported) and then assay for CT.  The experiment failed 
because the oyster was unable to survive longer than 6 hours.  The development of this 
assay was dependent on the survival of the oyster and the growth of V. cholerae.  In spite 
of the fact that toxin production could not be elicited in the tank simulation, it was 
induced in vitro in three separate strains of V. cholerae, which provided a natural source 
of the toxin. 
 A VET-RPLA detection kit (Oxoid) exists on the market that requires 24 hours 
enrichment of a pure culture of V. cholerae before the agglutination assay can be 
performed (146, 177).  The limit of detection for the kit is currently 1-2 ng/ml of CT 
(177).  The assay developed in this research has the ability to detect CT in the presence of 
cells without enrichment within a 20 minute time period with a limit of detection of 1 
ng/ml.  Conventional methods and VET-RPLA require the growth of the organism.  Any 
assay requiring enrichment would take longer than the 20 minute required for the Analyte 
2000.  Molecular methods such as PCR can be used to assay for virulent V. cholerae (21, 
96, 98, 122).  However, the inhibitory substances present in complex matrices such as 
food require sample processing before any testing can be performed (39, 96).  The assay 
developed in this research was not inhibited by any substances which may be found in the 
food matrix.  The only problem encountered with the oyster was the presence of two 
cross reactive proteins, which was overcome with fractionization of the oyster 
homogenate.   
 The ability of the Analyte 2000 assay to detect CT in a complex food matrix 
could be applied to other matrices as well.  Fecal material and vomit are two other 
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complex matrices in which CT may be found.  The utilization of the P10 gel column for 
sample fractionation could possibly allow for the detection of cholera toxin in these 
matrices.  The assay developed in this study showed that, if CT is present at 10 ng/ml or 
higher in the oyster matrix, the Analyte 2000 has the capability to detect its presence. 
   The ganglioside-based assay is a comparable alternative to an antibody-based 
assay, (sensitivity of 1 ng/ml).  Use of the ganglioside as the capture molecule and the 
antibody as the detection molecule conferred double specificity to the assay:  receptor-
toxin specificity and toxin-antibody specificity.  The causative agent of cholera is 
ultimately CT itself.  Toxin detection in lieu of detecting the organism is a more direct 
measure of pathogenicity.  The assays developed within this project successfully detected 
the presence of commercial and natural sources of cholera toxin in buffer, in the presence 
of cells and within the matrix of an oyster. 
 The CDC currently lists Clostridium botulinum toxin as a category A critical 
agent (142).  With an LD50 of 1 ng/kg of body weight in humans (53, 59, 163), a human 
oral lethal dose for type A toxin at 1 µg/kg (47, 163), botulinum toxin is one of the most 
potent biological toxins available (29, 53, 59, 163).  Unlike the cholera toxin assay 
developed in this research, the botulinum assay would need to be extremely sensitive.  
Research has shown that detection is possible with a colorimetric ELISA at 20 pg/ml for 
type A and B toxin (1), with the mouse bioassay at a MLD of 10-30 pg (47, 181) and 
with a ganglioside-liposome immunoassay at a toxin concentration of 15 pg/ml (1).  
Consequently, the botulinum assay must have a limit of detection on the order of at least 
2-3 logs more sensitive than the cholera toxin assay to be competitive with other assays 
available. 
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 Both the antibodies and type A and B botulinum toxins used for the development 
of this assay were obtained from the CDC.  Exact protein concentrations of the toxins 
were not available.  Although a BCA protein assay was performed to determine toxin 
protein concentrations, the results were inconclusive.  Two of the three antibodies 
received from the CDC had an affinity for the toxins and the commercial antibody 
purchased from Accurate displayed no affinity for either toxin.   
 An ELISA verified antibody-toxin specificity; it was therefore determined that the 
inability to generate a positive signal with the ELISA involved ganglioside-toxin 
specificity.  Initially, indirect ELISAs with the two gangliosides specific for botulinum 
toxin, GT1b and Gd1b, passively adsorbed to the wells of a microtitre plate were 
performed like those used to detect CT:  neither showed any specificity for the toxin.  
Detecting botulinum toxins with the use of a ganglioside, GT1b or GD1b, had been 
achieved when it was incorporated in a liposome (1, 156).  Creation of a liposome assay 
was attempted.  Several attempts to prepare liposomes incorporated with the ganglioside 
failed.  Custom liposomes were synthesized for the development of this assay by Dr. 
Anup Singh at Sandia National Laboratories in Livermore, California (156).   
 GT1b was selected as the ganglioside for incorporation into the liposome.  A 
fluorophore conjugated to a phospholipid was required for the liposome.  Cyanine 5 
conjugated to a phospholipid was not available commercially; therefore, a fluorophore 
with similar spectral characteristics to Cyanine 5 was selected. The Cyanine 5 
fluorophore has an excitation at 635 nm with an emission at 670 nm and the Alexfluor 
647 fluorophore has an excitation at 633/635 nm and an emission at 668 nm.  Alexaflou-
647 conjugated to a phospholipid was available commercially from Molecular Probes and 
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was selected for incorporation into the custom liposomes.  The emission of the 
Alexafluor 647 was out of the range of the Gemini fluorometer; therefore, ELISAs 
typically used in assay development were not used to assay for ganglioside-toxin 
specificity. 
 Initial work on the botulinum assay utilizing the Analyte 2000 was performed 
using toxoid type A and the CDC-goat anti-type A antibody.  Of the five possible 
antigen-antibody combinations, the CDC-goat anti-type A antibody displayed the highest 
affinity for its respective toxoid.  The protein was passively adsorbed to the polystyrene 
waveguide followed by incubation with the liposome.  It appeared that this assay had 
some potential in that there was a significant increase, of three- to five fold, in signal for 
three out of four of the Analyte 2000 channels; however, the negative control channel 
fluorescence signal doubled.  The increase in signal for the negative control was 
attributed to liposome sticking non-specifically to the polystyrene waveguide.  Further 
attempts were made in assay development with type A toxoid utilizing a biotinylated 
capture antibody bound to the waveguide via a streptavidin bridge.  Assays utilizing this 
sandwich immunoassay format were unsuccessful as well:  the LODs ranged in values 
from 53-3100 pA.  In order to try and reduce the LODs and obtain positive signals 
several variables were manipulated: the concentration of the liposome was changed, the 
toxin concentration was varied, specificity was tested using a different ligand, blocking 
buffers and times were varied and different wash buffers were used.  Regardless of the 
variable altered, the assay continued to produce high LODs and negative results.   
 With the limitations of the assay utilizing type A toxoid, attempts were made to 
try and develop the assay using type B toxoid.  As illustrated previously, the antibody for 
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the type B toxoid had a lower signal to noise ratio with the ELISA than the one used to 
capture the type A toxoid.  The assay followed the exact same format as the one used for 
the type A toxoid:  a sandwich immunoassay with the liposome as the detection 
molecule.  The assays were unsuccessful with LODs ranging from 163-3100 pA.   
 Limitations on the successful development of this assay for botulinum toxin could 
not be resolved.  The nonspecific binding of the liposomes to the polystyrene waveguide 
and the inability to reduce the LODs contributed to the failed attempts to develop this 
assay.  Even though the assay itself was not successful, valuable information was 
obtained from the study.  It is not advisable for future assay development with the 
Analyte 2000 to utilize liposomes as detection molecules.  The liposomes are expensive 
compared to most antibodies and they do not produce practical results.  The research 
conducted in this study with liposomes and the Analyte 2000 will hopefully influence 
others not to utilize them as detection molecules.  Even though gangliosides could not be 
utilized in the botulinum assay, this does not rule out the possibility of using strictly 
antibodies with this platform as capture and detector molecules.   
 Bioterrorism is a serious threat to the United States and to the world and cholera 
has re-emerged as a major infectious disease worldwide.  Documented events of 
bioterrorism have occurred since 184 B.C. and, with the advances in science and 
technology, transportation systems and the availability of select agents, such events 
remain a possibility today (29).  It is with the safety of the public health in mind that both 
public and private sector entities are focusing on the development of technology to detect 
biological agents (94).  The evanescent wave fiber-optic biosensor represents one form of 
technology with the capability to produce rapid, sensitive and specific assays for the 
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detection of CT.  This research has shown that gangliosides can be used in a biosensor 
assay to rapidly detect CT.  The Analyte 2000 has the capability to produce near real-time 
results with minimal sample preparation and the biosensor represents an alternative 
method for the detection of bacterial products such as toxins. 
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